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INTRODUCTION 
Over the past few years, Platelet Rich Plasma (PRP) has created a huge 
significance in several medical grounds, including orthopaedics. Numerous 
studies have shown that Platelet Rich Plasma can be used in the management 
of bony as well as soft tissue injuries. Lately, Platelet Rich Plasma has been 
used for chronic enthesopathies like tennis elbow, plantar fasciitis, in sports 
medicine and also in cartilage regeneration. 
Platelet Rich Plasma is a portion of blood with platelets concentrated in 
plasma. The functioning of platelet rich plasma is mainly governed by the 
growth factors in the alpha-granules. TGF-BETA 1, PDGF, VEGF, EGF are 
the growth factors seen in platelet granules. Their main role lies on the healing 
process of many tissues.  Platelet derived growth factor (PDGF) has mitogenic 
activity for both osteoblast as well as mesenchymal cells. PGF also has 
mitogenic potential which will regulate collagen production. VEGF-vascular 
endothelial growth factor, TGF-β transforming growth factor beta, FGF-
fibroblast growth factor, CTGF-connective tissue growth factor, IGF-insulin 
like growth factor have analogous properties.  It is because of the above growth 
factors, that Platelet Rich Plasma is a suitable substance for differentiation and 
regeneration of tissues. 
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The main uses of Platelet Rich Plasma- 
 Acute ligamentous injuries 
 Muscle injuries 
 Chronic tendinopathies 
 Also along with bone grafting 
 
 Tennis elbow (lateral epicondylitis) is a degenerative tendinopathy of 
extensor carpi radialis brevis muscle. It is commonly caused by repetitive 
micro trauma of the muscle due to overuse resulting in tendinosis of ECRB 
with or without involvement of extensor digitorum communis muscle. 
 With increased biological healing capacity, Platelet Rich Plasma helps in 
the cure of tennis elbow and also the relapse rate will be low. In our study, we 
used Ultrasound Guided Intralesional injection of autologous Platelet Rich 
Plasma and Corticosteroid injection for the treatment of chronic tennis elbow. 
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AIMS AND OBJECTIVES 
 
 
To assess the efficacy of ultrasound guided autologous Platelet Rich 
Plasma and Corticosteroid injection. 
To compare Autologous PRP (Platelet Rich Plasma) Vs Corticosteroid 
injection in terms of efficacy and its functional outcome. 
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TENNIS ELBOW 
 
Tennis elbow is a condition, characterized by pain and tenderness over 
the lateral epicondyle of the humerus, and pain on resisted dorsiflexion of the 
wrist, middle finger or both. Tennis elbow (lateral epicondylitis) is a common 
orthopaedic condition in the 4th decade of life. The tissue usually fails to 
demonstrate inflammation, even though the term ‘epicondylitis’ means 
inflammation. About 40% to 50% of recreational tennis players will suffer this 
condition during their lifetime.16,33 Although pain around the lateral epicondyle 
is commonly referred to as tennis elbow, tennis players make up only 10% of 
the patient population. Half of tennis players develop pain around the elbow, of 
which 75% represent true tennis elbow. The incidence is equal among men and 
women in the general population. The other names for this condition are lateral 
epicondylitis, peritenditis of the elbow, lateral elbow pain and tendonitis of the 
common extensor origin. 
 In most cases of lateral epicondylitis, no obvious underlying etiology 
can be identified. It starts as micro tear mainly in the origin of EXTENSOR 
CARPI RADIALIS BREVIS. The microscopic appearance is that of immature 
reparative tissue resembling angio-fibroblastic hyperplasia. 
The tendon fibers attached to the periosteum over lateral epicondyle are 
relatively avascular and are subjected to ischemic stress and thus slow to heal. 
Many others did not find evidence of inflammation in chronic tennis elbow and 
it was suggested that the term epicondylosis should be used instead of 
epicondylitis. 
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PREDISPOSING FACTORS 
 Conditions resulting in reduction of the carrying angle 
 Weight lifting in supinated and extended forearm 
 Sudden vigorous supination  
 Work which uses repeated pronation and supination 
movement.21 
Factors determining the chronicity of the lesion would be rheumatoid 
arthritis, gout and focal sepsis.21 
Tennis elbow has an uncertain pathology.40 As per one of the concepts, 
tendinosis mainly results due to the repeated wrist extensor muscle contraction 
which further leads to the microscopic tears. Local pathology consists of 
degeneration, disorganized collagen and neovascularity. 
The exact cause of pain and degeneration in these patients is not clearly 
known but neural, vascular or healing failure has been proposed. Pain increases 
with resisted dorsiflexion of wrist and supination of forearm and there is pain 
on grasping objects. 
According to Robert E Bunata et al conclusion, extensor carpi radialis 
brevis tendon has a distinct location, thereby making the area below it 
susceptible during the contact and abrasion against the capitellum during elbow 
movements.40 
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Knaushaar and Nirschi found that, surgical specimens obtained from 
failed treatment for tennis elbow by histology and electron microscopy had no 
evidence to suggest inflammatory process. 
STAGES OF TENNIS ELBOW 
 Early inflammatory reaction 
 Angiofibroblastic degeneration 
 Structural failure  
 Fibrosis or calcification.38 
Pathology: 
 Non inflammatory, chronic degenerative changes of the origin of the 
EXTENSOR CARPI RADIALIS BREVIS muscle. 
 ECRB muscle originates slightly medial and superior to the outer edge 
of capitellum on humerus, hence it is anatomically vulnerable to get 
compressed between EXTENSOR CARPI RADIALIS LONGUS and 
capitellum. 
 The condition is caused by partial tearing of the tendon fibers at their 
attachments to the epicondyle and the epicondylar ridge and the 
constant muscle contractions thereby prevent healing. 
 NIRSCHL and PETTRONE observed disorganization of normal 
collagen architecture by invading fibroblasts in association with an 
immature vascular reparative response, which is called 
ANGIOFIBROBLASTIC HYPERPLASIA.5 
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 Histology examination shows vascular proliferation and hyaline 
degeneration rather than inflammatory process. 
 ZEISIQ et al found evidence of local, non-neuronal production of 
catecholamine in the fibroblasts, in the tissue at the muscle origin, and 
at the lateral epicondyles in patients with tennis elbow.5 
 BOSWORTH et al demonstrated that the annular ligament undergoes 
hyaline degeneration and may be the source of pain. He reports tennis 
elbow cures by resection of the ligament, but in addition he severed or 
resutured the common tendon.5 
Age Group: 
 35-54 years is the most common age group to be affected. Most 
commonly affected being the dominant arm.17,33 Whenever there is increased 
work requiring resistance to wrist extension the patients commonly 
experiences burning or painful sensation over the lateral humeral epicondyle.46 
COMMON PALPATION FINDINGS 
 Decreased grip strength 
 Tenderness at the lateral epicondyle 
 Tenderness along the common extensor tendon.46 
There are certain tests such as Cozen’s test and Mill’s maneuver that 
acts as efficient diagnostic tool generating pain by resisted extension of wrist. 
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Plain radiographs are normal. MRI shows tendon thickening with 
increased T1 and T2 signals. On an average, a typical episode of lateral 
epicondylosis lasts 6-24 months.  
Waseem M et al explained that this condition is not an inflammatory 
process with no inflammatory cells (macrophages, lymphocytes, neutrophils) 
could be detected in the affected tissue. But, it is a form of tendinosis that 
affects the common extensor tendon with a fibroblastic and vascular response 
called angiofibroblastic degeneration of common extensor tendon.53 
Ultrasound guidance of the injection will ensure precise targeting of 
tissue needle placement and real time visualization of needle during injection 
with documentation of changes in tendon morphology and structure after PRP 
injection. 
CONSERVATIVE TREATMENT 
 Non-steroidal anti-inflammatory drugs 
 Ice application 
 Braces  
 Physiotherapy 
 Rest. 
 Platelet rich plasma a bioactive component of whole blood, helps in 
regeneration of tissues with poor healing ability and being useful in varied 
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medical fields. For chronic tennis elbow patients, the study on platelet rich 
plasma versus autologous whole blood was done by Christos Thanasas et al 
and thereby supports the use of PRP in the management of tennis elbow.9 
Mishra A et al described positive results of platelet rich plasma injection in 
patients with tennis elbow.32 
HISTORY OF PLATELET RICH PLASMA 
Platelet rich plasma is also known as platelet rich growth factor, platelet 
rich fibrin matrix, platelets concentrate. 
The concept and description of PRP started in the field of hematology. 
Hematologists created the term PRP in the 1970s in order to describe the 
plasma with a platelet count above of that of peripheral blood, which was 
initially used as a transfusion product to treat patients with thrombocytopenia. 
Subsequently, PRP has been predominantly used in the musculoskeletal 
field in sports injuries. With its use in professional sports persons, it has 
attracted widespread attention in the media and has been extensively used in 
this field. 
Other medical fields that also use PRP are cardiac surgery, pediatric 
surgery, gynaecology, urology, plastic surgery and ophthalmology.  
More recently, the interest in the application of PRP in dermatology 
such as in tissue regeneration, wound healing, scar revision, skin rejuvenating 
effects, and alopecia. 
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Wounds have a proinflammatory biochemical environment that impairs 
healing in chronic ulcers. In addition, it is characterized by a high protease 
activity, which decrease the effect of growth factor concentration.  
PRP is used as an interesting alternative treatment for recalcitrant 
wounds because it is a source of growth factors and consequently has 
mitogenic, angiogenic and chemotactic properties. 
In cosmetic dermatology, a study performed in vitro demonstrated that 
PRP can stimulate human dermal fibroblasts proliferation and increase type 1 
collagen synthesis. Additionally, based on histological evidence, PRP injected 
in human, in deep dermis and immediate sub dermis induces soft tissue 
augmentation, activation of fibroblast and collagen deposition, as well as new 
blood vessels and adipose tissue formation. 
Another application of PRP is the improvement of burn scars, 
postsurgical scar and acne scars. According to the few articles available, PRP 
alone or in combination with other techniques seems to improve the quality of 
the skin and leads to an increased in collagen and elastic fibers. 
In the 1980s, the advent of regenerative medicine aiming to rapidly 
translate the science into patient care using, the patient’s own blood resources 
opened the door to use the platelets as vehicle for the delivery of a balanced 
pool of healing factors. 
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At the time, platelets were found to release wound healing substances 
that initiated the repair of injured tissues and vessels in cutaneous ulcers.   
Later in the 1990s, platelets were introduced into maxillofacial surgery 
as autologous modifications of potent adhesives known as fibrin glue. A 
realization of the clinical potential of PRP therapies followed the positive 
clinical observations such as enhanced bone formation and anti-inflammatory 
functions during oral and maxillofacial surgeries (Whiteman et al.54, 1997; 
Marx et al29., 1998, Anitua E et al., 1999). 
At the beginning of the millennium, PRP was used for the first time to 
treat the knee injuries in arthroscopic surgeries (Sanchez et al., 2003) and later 
it was extended to the treatment of tendons (Sanchez et al., 2007), muscle 
injuries (Sanchez et al., 2005), osteoarthritic knees (Schanz et al., 2008) and 
hips (Sanchez et al., 2011) and for use in chondropathies (Kon et al., 2010). 
In 2006, PRP has started to be considered a potential therapeutic tool for 
promoting hair growth and tendon healing. Several studies have been published 
that refers to the positive effect PRP has an androgenic alopecia, wound 
healing and tendon healing. 
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PLATELET RICH PLASMA 
Portion of the plasma fraction of autologous blood having a platelet 
value above baseline. Platelet rich plasma consists of full complement of 
clotting factors and secretory proteins along with the platelets.45 
Bone marrow is the site of production of platelets from the 
megakaryocytes. Lifespan of a platelet cell is around 5-9 days.  
Their direct contact with various extra-cellular proteins is established by 
the formation of platelet plug which is formed after tissue injury or surgery 
following platelet exposure to the damaged blood vessels.45 
Normal platelet count – 150000/microliter and 350000/microliter, and 
average about 200000/microliter in blood.29 M Ferrari (1987) was the first to 
promote platelet rich plasma as an autologous component after an open heart 
operation to avoid homologous blood product transfusion.34 
Platelet Rich Plasma is an autologous product that concentrates a large 
number of platelets in a small volume of plasma. PRP functions as a fibrin 
tissue adhesive with hemostatic and tissue sealing properties, but it differs from 
fibrin glue and other platelet–poor tissue adhesive because its platelets provide 
a unique ability to promote wound healing and enhance osteogenesis. 
PRP provides an immediate surgical hemostatic agent that is 
biocompatible, safe, and effective. PRP accelerates endothelial, epithelial, and 
epidermal regeneration, stimulates angiogenesis, enhances collagen synthesis, 
promotes soft tissue healing, decreases dermal scarring, and enhances the 
hemostatic response to injury.  
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The high leucocytes concentration of PRP has an added antimicrobial 
effect. Since PRP is an autologous blood product, it carries no risk of 
transmitting infectious disease. 
Platelets are cytoplasmic fragments of megakaryocytes, formed in the 
bone marrow. They contain 30 bioactive proteins, many of which have a 
fundamental role in hemostasis or tissue healing. Few fundamental protein 
growth factors that are actively secreted by platelet initiate all wound healing 
process. 
PRP also includes three proteins in blood known to act as cell adhesion 
molecules; Fibrin, Fibronectin, and Vitronectin. 
Activation causes the granules present in platelets to fuse to its cell 
membrane where the secretory proteins are transformed to a bioactive state by 
the addition of histones and carbohydrate side chains.  
The active proteins are then secreted, binding to transmembrane 
receptors of target cells, which includes mesenchymal stem cells, osteoblasts, 
fibroblasts, endothelial cells and epidermal cells. These agonists bound 
transmembrane receptors then activate an intracellular signal protein that 
causes the expression of a gene sequence that directs cellular proliferation, 
osteoid production, matrix formation and collagen synthesis.  
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CLASSIFICATION OF PRP: 
According to the classification proposed by Ehrenfest DM et al. four 
main families of preparations can be defined, depending on their cell content 
and fibrin architecture.15 
1. Pure Platelet Rich Plasma or Leucocyte-poor PRP products are 
preparations without leucocytes and with a low-density fibrin 
network after activation. 
2. Leucocyte and PRP (L-PRP) products are preparations with 
leucocytes and with a low-density fibrin network after activation. 
3. Pure Platelet Rich Plasma fibrin (P-PRF) or leucocytes-poor platelet 
rich fibrin preparations are without leucocytes and with a high-
density fibrin network. 
4. Leucocytes and platelet rich fibrin (L-PRF) or second generation 
PRP products are preparations with leucocytes and with a high-
density fibrin network. 
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ROLE OF BIOACTIVE FACTORS: 
 Bioactive factors promote and accelerate the healing process and are 
stored and released by platelet alpha and dense granules.7 
 Alpha granules are reservoirs for numerous growth factors cytokines, 
chemokines and various coagulation and adhesive proteins.7 
 Growth factors released by alpha granules include vascular endothelial 
(VEGF), transforming beta (TGF-beta), platelet derived (PDGF), platelet 
derived epidermal (PDEGF), fibroblast derived growth factors and epidermal 
(EGF).22 
 Bioactive factors released by dense granules such as serotonin, 
histamine, calcium, adenosine diphosphate, adenosine triphosphate and 
dopamine. It is theorized that pain relief experienced by patients after PRP 
injection may result from the release of factors such as serotonin and 
catecholamine from dense granules.7 
Platelet Biology 
 All blood cells derive from a common pluripotent stem cell, which 
differentiates into different cell lines. Platelets are nucleated, discoid cellular 
elements with different sizes. Platelet contain several secretory granules that 
are crucial to platelet function. There are 3 types of granules. 
 dense granules 
 o-granules 
 lysosomes 
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In each platelet there are approximately 50-80 granules, the most 
abundant of the 3 types of granules. Platelets are primarily responsible for the 
aggregation process. The main function is to contribute to hemostasis through 3 
processes; adhesion, activation and aggregation. 
 During a vascular lesion, platelets are activated and their granules 
release factor that promote coagulation. Studies suggest that platelets contain 
an abundance of growth factors and cytokines that can affect inflammation, 
angiogenesis, stem cell migrations, and cell proliferation. 
Platelets release their contents and a cascade of event is initiated. 
Normal collagen is repaired. Collagen repair consists of the following phases; 
inflammation, proliferation and remodeling. Each of these stages is needed to 
restore the normal function of the tissue. 
The presence of white blood cells in PRP may affect its use, independent 
of concentration of the platelets. Once platelets are activated, platelet 
aggregation occurs and the contents of their solid granules and alpha granules 
is released. 
The activation of platelets in vivo is done in three ways; by adenosine 
diphosphate via membrane phospholipids system and inducing the presence of 
thrombin. 
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Functions of platelets: 
Besides participation in hemostasis, platelets also have other functions. 
To obtain hemostasis, the interaction of three main mechanisms is necessary; 
vascular response, platelet activity and clot formation. The sub-endothelial 
Willebrand factor, are the main factor that activate blood platelets in vivo, as 
well as thrombin, adenosine diphosphate or a combination of them. 
One of the essential factor for tissue healing is platelet.22 The tissue 
healing begins with the platelet activation and clot formation.22 The platelets 
act by means of various growth and differentiation factors.22 They help in 
attracting mesenchymal stem cells, macrophages and osteoblasts which 
enhances tissue healing and regeneration and also helps in removal of necrotic 
tissue. 
TGF-beta 
1. regulates collagen synthesis 
2. stimulates endothelial chemotaxis and angiogenesis 
3. inhibits macrophage and lymphocyte proliferation.22 
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Platelet concentration related to tissue specific: 
Different tissue types may require different platelet concentrations to 
achieve the optimal response to PRP administration. Receptor level vary 
between tissues, therefore ideal PRP concentrations may vary as well. This 
may explain why a specified concentration produces significant effects in one 
study with a specific tissue type and does not show an effect in another study 
involving a different tissue1. 
Anitua E et al, were able to demonstrate this when they studied the 
effects of 2 x and 4 x PRP on tendon, dermal and synovial fibroblasts. They 
demonstrated different positive effects for both platelet concentrations with 
respect to proliferation, hyaluronic acid production and secretion of angiogenic 
growth factors.1  However, the positive effect was not consistently the same for 
each tissue type.  
The authors concluded that the biological effects of preparations rich in 
growth factors may depend on concentration of platelets and on the anatomical 
source of the cells. 
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PRP activation by Cacl2 
Calcium chloride added exogenously to PRP preparation in lieu of 
bovine thrombin may result in the formation of a less condensed fibrin matrix. 
The fibrin matrix may provide a trapping mechanism for platelets resulting in 
smaller amounts of thrombin formation endogenously, allowing a slower 
release of growth factors over a 7-day period which may enhance cell 
migration and healing. 
Betoni Junior W et al, evaluated bone healing effects with the use of a 
bone graft with PRP combined with Cacl2, and thrombin compared with Cacl2 
only.6 After histological analysis, both methods presented good bone repair 
with similar maturity, organization and vascularization.  
The results from this paper demonstrated that Cacl2 was an adequate 
activator of PRP when used alone, but thrombin also yielded a positive effect.6 
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GROWTH FACTOR FUNCTIONS RELATED TO PRP 
 
 
GROWTH FACTORS PRIMARY FUNCTIONS 
Epidermal Growth Factor Regulation of cell proliferation and 
survival 
Insulin like Growth Factor Key regulator of cell metabolism 
and growth stimulates proliferation 
and differentiation function in 
osteoblast 
Platelet Derived Growth Factor Major mitogen for connective tissue 
cells & Promotes the synthesis of 
collagen and structural proteins. 
Transforming Growth Factor 
(alpha, beta) 
Regulation of cell proliferation and 
differentiation and apoptosis and 
induction of intimal thickening. 
Vascular Endothelial Growth 
Factor 
Regulation of angiogenesis 
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FUNCTIONS OF PLATELET CONNECTIVE TISSUE GROWTH 
FACTOR: 
 Promotes cartilage regeneration 
 Promotes fibrosis  
 Promotes angiogenesis.22 
 
EFFECTS OF PRP IN DIFFERENT TISSUES 
TENDON: 
The use of PRP in tendon injuries and tendinitis was given by Samir 
Mehtra in his article.45 This was also done by Steven Sampson in his article.44 
The effect of PRP on rabbit tendon was also stated by N Lindsay Harris.35 
Thick peritendon and cells of inflammation were observed at 2 weeks. Along 
with it, collagen bundles, vacuoles and inflammatory cells are also seen in the 
tendon tissue. 
At 6 weeks, peritendon shows inflammation. 
At 12 weeks, inflammation decreased. 
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Study on normal rabbit tissue was done by N Lindsay Harris35 and 
found that at two weeks, there was thick tissue with inflammation and at 6 and 
12 weeks there was minimal inflammation after PRP injection. 
 
MUSCLE: 
Kenneth S Lee22 in his article stated about Cugat et al research on 
acute muscle injuries with PRP.  The microscopic changes in normal muscle 
tissue following PRP injections was assessed on rabbit tissues by N Lindsay 
Harris.35 The study was done on 18 rabbits by injecting 0.5ml of PRP into the 
tissues. 
Features suggesting inflammation was found by him after two-weeks of 
platelet rich plasma injection. The inflammatory cells were observed in the 
tissue along with calcium deposition which was also seen. 
The inflammation stayed even after six weeks of injection. The 
inflammatory cells were seen. The calcium which was deposited was 
reabsorbed later. 
After 12 weeks, no indications regarding inflammation were noticed. 
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WOUND HEALING: 
Platelet rich plasma ensures proper acceleration of the wound healing. 
Since there is increased amount of platelets in PRP, it helps in wound healing 
by release of growth factors. Several studies have been done by means of 
human trials and animal models thereby providing the information regarding 
the effect of PRP on wound healing. 
 
 
 
 
 
 
 
 
 
 
 
 
In his literature on platelet rich plasma, Samir Mehtra explained about 
the studies conducted by Knighton D R et al26 and C Gaino et al.  17 out of 
21 patients had re-epithelialization and 78 percent of patients had limb salvage 
in Knighton D R et al and C Gaino et al studies respectively. Platelet Rich 
Plasma has also got application in case of split skin graft as it can be used in 
the donor site. PRP reduces the crusting interval and also helps in accelerating 
the epithelialization. 
PHASES OF WOUND HEALING AND THE TIME OF 
PLATELET ACTION 
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 In his literature on the effect of platelet rich plasma on musculoskeletal 
injuries, Steven Sampson has explained about the studies of Crovetti et al and 
McAleer et al. Twenty out of twenty four and nine out of twenty four had 
complete healing of the chronic ulcers in McAleer etal and Crovetti et al 
studies respectively. 
 
BONE 
The relationship between the effect of platelet rich plasma and bone 
healing has always been a topic of debate. Most of the studies had positive 
results, even though some of the animal studies not supporting PRP use.  
 
When used along with bone grafts, growth factors like PDGF and   
TGF-beta can lead to bone healing. Alsousou J et al4 did an article on the 
application of platelet rich plasma in orthopaedics, and in this there was 
statement about the study done by Bielecki et al and found that 13 out of 20 
non unions, complete union was obtained after PRP application. 
 
A study on assessment of the levels of growth factors in fracture 
hematoma in the same article above found that, no growth factors were found 
in nonunion. In the same article, a study of Kitoh H et al on distraction 
osteogenesis was explained and callus formation was observed at 34 to 47 
days.24 
The use of PRP in fractures in diabetic patients was also commented by 
Alsousou J. It was observed that growth factors were low in case of diabetic 
fracture callus. The healing process in the diabetic fractures can be accelerated 
once Platelet Rich Plasma is infiltrated.4 In his article on platelet rich 
concentrate Samir Mehtra explained about the use of PRP in nonunion.45  
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 He specified that platelet rich plasma can promote bone healing if 
adequate approximation of bone was present and not in gap nonunion. 
 
JOINTS: 
In his study on rabbit, N Lindsay Harris injected PRP into the normal 
tarsal joint with a control of normal saline injection. He observed features 
associated with synovitis in all with nodules in one specimen at two weeks.35 
 
 
 
 
 
 
 
 
 
 
 
 
He also observed histological response similar to calcification in 
subcutaneous tissue at four weeks. At six weeks and twelve weeks all the 
specimens show normal findings as in normal saline specimen.35 
  
Fig A: SPECIMEN WITH NORMAL 
SALINE INJECTED 
Fig B: SPECIMEN WITH 
PLATELET RICH PLASMA 
INJECTED 
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THIS IMAGE SHOWS THICKENING OF COMMON 
EXTENSOR TENDON (7.64 mm) 
 HETEROGENOSITY (RED ARROW) MORE THAN 
2/3rd OF TENDON 
 OSTEOPHYTE FORMATION (PURPLE ARROW) 
AND CORTICAL IRREGULARITY OF LATERAL 
EPICONDYLE SURFACE 
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PRP function related to fractures and delayed union or nonunion 
 
PRP has demonstrated osteogenic properties in several invitro and 
preclinical studies, as shown in a review by Iqbal et al.18 PRP was used in 
conjunction with other augments (bone graft, bone marrow concentrate) 
making it difficult to ascertain the relative contribution of platelet rich plasma. 
In a study of 30 patients with distal radius fractures, Namazi H and Mehbudi 
compared a single intraarticular injection of PRP immediately after 
percutaneous fixation.36 
 
The PRP group reported better improvement in pain and activity scores 
compared with the control group at 3 and 6 months. 
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SAFETY OF PLATELET RICH PLASMA 
 
The safety of autologous concentrate was given by Samir Mehtra in his 
article on platelet rich concentrate.45 He explained that as it is prepared from the 
patient’s own blood, the risk of communicable transmission is nil. In this he 
also stated that regarding the contraindications of platelet rich plasma in 
patients affected with coagulation disorders and hypersensitivity to the 
products like bovine thrombin. 
Joost C Peerbooms et al in a study about tennis elbow with PRP 
observed that there was no local and systemic complications apart from 
increased pain during the first few days after PRP injection due to the 
inflammatory process.20 
Bielecki et al in a study to find the antibacterial effect of autologous 
PRP against methicillin sensitive staphylococcus aureus and supports the 
growth of Pseudomonas aeruginosa.8 
PLATELET RICH PLASMA PREPARATION:  
       Regarding the preparation of PRP, there are 2 techniques: 
Open technique 
The product is exposed to the environment of the working area and comes 
in contact with different materials that should be used for their production, 
such as pipettes or product collection tubes. In the blood processing to obtain 
PRP with the open technique, it should be guaranteed that the product is not 
contaminated during microbiological handling. 
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Closed technique 
It involves the use of commercial devices with centrifuge equipment 
marking in which the product is not exposed to the environment. Several 
centrifuge equipment devices are available for the production of autologous 
PRP. Most of them are included in one of the following 3 types of devices. 
1. The blood is obtained with a tube that contains an anticoagulant, and 
this tube can be used for any type of centrifuge. 
2. Medical devices with which the blood is collected into a tube that 
already contain an anticoagulant.  
3. Medical devices with which the blood filled is collected into a 
syringe previously filled with an anticoagulant; usually, the blood is 
transferred into a secondary device whose shape imposes the use of 
the centrifuge supplied by the same manufacturer. The preparation 
of PRP depends on the type of device chosen and should be done 
according to the manufacturer’s instructions. 
          Different studies used various methods for preparing PRP. 15 ml of 
patient own venous blood was withdrawn from antecubital vein under aseptic 
conditions and was collected in presterilized centrifuged four vacutainers vials. 
These centrifuge vials were preloaded with anticoagulant Acid Citrate 
Dextrose. These four vacutainers were subjected to a first spin in a centrifuge 
at a speed of 2500 rpm for 10 minutes. 
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After the first spin three layers appear,  
 The deep layers consist of RED BLOOD CELLS 
 The middle layers consist of PLATELETS AND LEUCOCYTES.  
 The top layers consist of PLATELET POOR PLASMA 
 The top and middle layers were transferred to a fresh vacutainer. The 
plasma was then subjected to a second spin at a speed of 3500 rpm for 15 
minutes. The plasma at the bottom which is rich in platelets was separated and 
used for infiltration. The resulting platelets concentrate contains 6-8 times the 
concentration of platelets compared to baseline whole blood. 
PRP ACTIVATION 
Platelet rich plasma results in increased release of growth factors with 
90% released in 10 minutes. PRP can be stimulated by calcium chloride and 
thrombin exogenously and by mechanical trauma endogenously. Most growth 
factors have short half life. 
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The enmeshment of growth factors and cells is stimulated by a more 
stable tetra molecular network initiated by a physiological manner. 
 
Accidental stimulation can happen by injuring cells and also by braking 
systems of the centrifuge machines. To prevent this, while drawing blood large 
bore needles should always be used.  
 
PRP, which is obtained at a higher concentration than full blood, is an 
encouraging treatment option. Biologically active proteins expressed by active 
platelets lead to gene expression by binding to the transmembrane receptors in 
the target cells. As a result, cellular recruitment, growth and morphogenesis are 
triggered and at the time, inflammation is reduced. 
 
PRP system that use the buffy coat contain an increased concentration 
of WBCs. Although normal level of WBC has a positive immunomodulatory 
effect, heightened levels in some PRP preparations may have deleterious 
effects. 
 
PLATELET RICH PLASMA
activated
FIBRIN 
PLASMA SOLIDIFIED AND 
FIBRIN CLOT FORMED 
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Platelet-rich leucocytes gel is thought to have potent antimicrobial 
effects. PRP containing WBCs may help prevent post-operative 
staphylococcus aureus infections. Other potential benefits of WBCs include 
removal of necrotic tissue through cellular engulfment of tissue by products, 
the release of proteolytic enzymes that breakdown necrotic tissue or release 
additional growth factors that may play a supplementary role in eliminating 
dead tissue.39,50 
 
Negative Effects of WBCs in PRP 
 
Specific WBCs, such as neutrophils and CD8+ lymphocytes, may be 
detrimental to PRP therapy. Neutrophils are not crucial to the overall process 
of wound healing and collagen synthesis. Infiltration of neutrophils causes 
release of oxygen free radicals during inflammation and has been shown to 
play a central role in ischemic tissue injuries. 
 
This may cause endothelial and subendothelial damage and lead to 
excessive fibrosis that can exacerbate a pre-existing injury and prevent healing. 
White blood cells also release catabolic cytokines, matrix metalloproteinase 
and interleukin-beta. 
 
These substances are regulators of inflammation and degradative 
turnover of tissue. 
 
Neutrophils also exacerbate muscle damage after an injury. It has been 
suggested that WBCs are detrimental in fracture healing by suppression of 
bone formation and bone healing. A study was performed to determine the 
effects of polymorphonuclear leucocytes in fracture healing. 
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Role of platelets in Healing 
The healing process can be divided into 3 phases; 
Phase1 (hemostasis and inflammation) is triggered by tissue injury 
and lasts for 2-5 days.  
During phase 1, platelets become activated when they encounter injured 
tissue and adhere to the exposed collagen, aggregating to form a clot.11 
Degranulation of platelets occurs and the release of growth, bioactive, and 
hemostatic factor results in inflammation. 
Platelets release 70-95% of the stored growth factors in the first 10 
minutes after tissue injury and additional growth factors continue to be 
secreted for 7-9 days.7,12 
Phase2 (proliferation) begins 2 days after injury and can last for 3 
weeks. 
These phase involves formation of blood vessels, collagen deposition 
via fibroblasts, wound contraction and continued release of small amounts of 
growth factors.7 
Phase3 (remodeling) follows and involves maturation of collagen and 
formation of scar tissue and can take more than a year to complete.7,8 
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Plasma based PRP 
Plasma based methods work to isolate only plasma and platelets 
components. Protocols for these preparations leave some platelets behind and 
focus on intentionally excluding leucocytes, which are thought to be 
detrimental to the healing process.  
Buffy coat based PRP 
Buffy coat based methods isolate a platelet poor plasma layer and a 
buffy coat layer, which contains both leucocytes and erythrocytes. Differences 
in concentration of platelets, and the presence or absence of white blood cells 
leads to different amounts of anabolic and catabolic proteins released to the 
target tissues after injection.  
Invitro study performed by Castillo et al tested three different PRP 
separations system, each system yielded similar platelet concentration, red 
blood cells, active TGF-beta and fibrogen levels.10 
A recent innovation of PRP, which is a component of blood in which 
the platelets are concentrated in a limited volume of plasma. Autologous 
platelet gel was first developed as a byproduct of multicomponent pheresis. 
The platelet count in PRP can exceed 2 million platelets per micro liter. A 
natural blood clot contains 95% red blood cells, 5% platelets, less than 1% 
white blood cells.  
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It can be considered that PRP jump starts the cascade of regenerative 
events leading to the formation of a mature graft site. The PRP obtained offers 
up to a 2.16 times increase in maturation rate and substantially greater density 
of a bone graft procedure. 
Components of PRP 
1. Growth factors 
2. WBC and phagocytic cells 
3. Native fibrogen concentration 
4. Vasoactive and chemotactic agents 
5. High concentration of platelets. 
Role of growth factor in PRP 
PRP is an autologous source of concentrated suspension of the growth 
factors found in platelets. Activated PRP release growth factors and enhance 
wound healing and wound strength. 
Growth factors derived from platelets initiate connective tissue healing, 
bone regeneration and repair, promote development of new blood vessels, and 
stimulates the wound healing process. 
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Platelet derived growth factor (PDGF) 
 PDGF is a very powerful regulatory growth factor and a sentinel growth 
factor that begins nearly in all wound healing. PDGF main function is to 
stimulate cell replication (mitogenesis) of healing capable stems and premitotic 
partially differentiated osteoprogenitor cells, which are part of the connective 
tissue-bone healing cellular make up. 
  PDGF also causes replication of endothelial cells, causing budding of 
new capillaries (angiogenesis). 
PDGF exists in three forms: 
PDGF-AA 
PDGF-BB 
PDGF-AB 
All isoforms of PDGF are released after adhesion of platelets to an 
injured site. The AA and BB isoforms enhance proliferation of bone cells, 
increasing the production of PDGF-AA in osteoblasts cultures. 
Transforming Growth Factors: (TGF) 
TGF regulates proliferation and differentiation of multiple cell types. 
TGF found in platelets is subdivided into TGF-beta1, TGF-beta 2, which are 
more generic connective tissue growing factors involved with matrix formation 
influencing osteoblasts to lay down bone matrix through the process of 
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ostegenesis. A chondroprogenitor cells will further differentiate and produce 
the matrix for cartilage. A mesenchymal stem cell stimulated to mitosis 
provides wound healing cells.  
In vitro, TGF-beta has been observed to promote extracellular matrix 
production in many cell types, such as tendon healing fibroblasts. TGF-beta 1 
used alone or in combination with PDGF-BB, stimulates the proliferative 
activity of tendon healing. 
Insulin Growth Factor (IGF) 
IGF is also important in tendon healing, and stimulates both 
proliferation and differentiated function in osteoblasts. IGF has two forms 1 
and 2 each of which has 2 single chain peptides. IGF1 stimulates bone 
formation by proliferation and differentiation, and it is synthesized and 
secreted by osteoblast. Human patients treated with a combination of 150mg/dl 
each of recombinant human platelet derived growth factor-BB. 
Epidermal Growth Factor (EGF) 
EGF is responsible for cell differentiation and stimulates re-
epitheliation, angiogenesis and collagenase activity. Vascular endothelial 
growth factor (VEGF) have potent angiogenic, mitogenic and vascular 
permeability enhancing activities specific for endothelial cells. 
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The short shelf life and inefficient delivery to target cells are major 
concerns associated with local administration of recombinant human growth 
factors. The growth factors are expensive, and many doses may be required to 
achieve any therapeutic effect. 
Major Benefits of PRP 
PRP starts osteogenesis by releasing growth factors at the local site. 
Osteoblasts are then moved across a greater distance by creating a scaffold 
system that will assist their movement. 
Early consolidation of the graft 
The increased amount of PDGF in the graft initiates osteocompetant cell 
activity at an enhanced molecular site. 
Speed up mineralization 
Because mineralization on a graft site is a coupled phenomenon, 
osteogenesis must proceed in such a way that activation and bone formation is 
greater than resorption.  Mineralization of the collagen matrix is speeded up 
due to PDGF being added right from the start in the mineralized bone segment 
of the graft, instead of being released from collagen. Use of PRP has shown to 
improve the rate of bone formation by 1.62 to 2.18 times that of the controls. 
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Improves trabecular bone density 
There has been reported in the literature that a 15% to 30% 
improvement in trabecular bone density when platelet rich plasma factor is 
added to the graft. 
 The native fibrinogen concentration imparts a gelatinous adhesive 
consistency, for ease of surgical application and results in reduction of pain 
and infection. 
Sequence of bone Regeneration 
Platelets are responsible for initiation of regeneration of tissue from 
trauma. During repair, platelets become entrapped in a fibrin clot and 
degranulate releasing two primary growth factors; PDGF and TGF-beta. PDGF 
binds to endothelial cells to initiate capillary ingrowth and TGF-beta binds to 
osteoblasts and stem cells to initiate mitosis and stimulate osteoid production. 
The life span of platelets in a wound is less than five days. Macrophages 
are attracted into the graft through an oxygen gradient of 30-40 mm Hg and 
drive the remaining bone regeneration process. 
By day 14, complete revascularization of the graft is seen. Stem cells 
differentiated into osteoblasts and osteoid is being laid down. Early bone 
formation occurs, by four to six weeks, random cellular bone called woven 
bone, is formed which is immature and disorganized. 
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In phase 2 remodeling lamellar bone is formed, representing a more 
organized bone. 
Stefano Gumina et al, used autologous thrombin for platelet 
activation.49Juan Ramon Valenti Nin et al, used 10% Cacl2 for activation of 
platelets intra operatively. That the force necessary for inducing rupture during 
tensile test was more for tendons which had a PRP injection than the control 
group.19 
HUMAN STUDIES IN PLATELET RICH PLASMA 
1. Taco Gosens et al done a study on patients suffering from chronic tennis 
elbow.51 Two treatment methods were used. Both platelet rich plasma and 
corticosteroid injections were used for the treatment. 100 patients were 
included in that study. Out of these 100 patients a computer based system 
allocated the patients into two groups. First group had 51 patients and 
second group had 49 patients. First group of patients were injected with 
platelet rich plasma and the second group was injected with steroid. VAS 
and DASH scoring system were used both before and after the injection for 
the evaluation of patient’s condition. Two years from the time of injection 
was the follow-up period. It was found that patients treated with PRP 
showed good improvement in their condition than those patients treated 
with steroid injection. Therefore, they concluded that platelet rich plasma 
had good effect in treating tennis elbow. 
 
 
  
 
 
43
2. Mishra A et al done a study in order to find the effect of using buffered 
platelet rich plasma on chronic severe elbow tendinitis.32 In this study, 140 
patients suffering from epicondylar elbow pain were included. All patients 
were dealt with physical therapy being a standardized protocol and other 
nonoperative treatments. For all patients, surgery was considered.  
 This cohort of patients who had failed conservative treatment was then 
given either a single platelet rich plasma or bupivacaine injection. It was 
observed that 8 weeks after the injection, the PRP group noted 60% 
improvement in their VAP scores and 16% improved in the control group. 
After the 8th week, 60% (3 of 5) of the control subjects withdraw or sought 
various treatments, preventing further direct analysis. At 6 months, 81% 
improvement in visual analog pain scores were observed in patients who got 
PRP treatment. During the final follow-up at 12-38 months, 93% reduction in 
pain was observed in the PRP patients compared with the before treatment. 
3. Ehab Mohamed SelemRagab et al done a study in order to observe the 
effectiveness of PRP treatment in case of chronic plantar fasciitis.14 The 
population of patient they selected was 25 and they injected the 25 
patients with PRP. VAS and USG thickness of the fascia were used for 
the assessment. They followed up for 10 months. They observed that, 
with the use of visual analog pain scale, the average pre-injection pain in 
patients was 9.1 (range 8-10). Prior to injection, 72% patients suffered 
from severe limitation of activities and 28% of patients had only moderate 
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limitation of activities. It was also observed that the average post-
injection pain decreased to 1.6.  
 Twenty-two patients (88%) were fully satisfied, two patients (8%) were 
satisfied with reservations, and one patient (4%) was unsatisfied with using the 
visual analog scale.14 
4. Suzan de Jonge et al done a study in order to find the use of PRP in 
treating tendinopathy. They opted Achilles tendinopathy for their study. 
The criteria by which this study was done was tendinopathy at 2-7cm 
from insertion of tendon. They selected 44 patients for their study. 
 USG was used for assessment during pre-injection and post-injection 
period and one scoring system was used. VISA was the scoring system that 
was used. A control group was selected to whom only saline injection was 
given. Patients of both the groups suffered from tendinopathy and both group 
underwent severe exercises. After the study period, they assessed the results 
and observed that the patients in both the group improved, by means of scoring 
system and by USG evidence. 59% of patients improved in both the groups and 
they cannot make any difference in the groups.43 
5. Leon Creaney et al in a study linked the effect of PRP with autologous 
blood injection in elbow tendinopathy.27 150 tennis elbow patients were 
selected and 80 patients were treated with PRP and the remaining 70 
patients were treated with whole blood.  
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They evaluated the patients by using PRTEE score. The authors observed a 
66% success at 6 months. 
6. Stefano Gumina et al done a study to assess the clinical and Magnetic 
Resonance Imaging (MRI) results of arthroscopic repair of rotator cuff 
both with and without the use of platelet-leukocyte membrane in patients 
with a large posterior-superior rotator cuff tear, observed that rotator cuff 
re-tears were found only in the group of patients in whom the membrane 
had not been used, and a thin but intact tendon was observed more 
frequently in this group.49 80 full thickness tear of rotator cuff patients 
were used and all the patients who underwent arthroscopic repair and 
randomly used platelet rich membrane for the treatment. Outcomes were 
the difference between the preoperative and postoperative constant scores 
and the integrity of repair was assessed by MRI as per the Sugaya 
classification. Another outcome they used was preoperative and 
postoperative Simple Shoulder Test Scores. The results portrayed that 
only significant differences between the two groups involved the patient 
age and the preoperative and postoperative constant scores; the 
differences in the constant score were due to differences in the shoulder 
pain  subscore. 
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MATERIALS AND METHODS 
This is a prospective trial involving the patients in the Department of 
Orthopaedics, Government Kilpauk Medical College and Hospital from April 
2017 to April 2018. Approval was obtained from Ethics Committee for 
Research in human beings before this study. 
A total of 220 patients were included in this study. Out of this, 110 
patients were injected with PRP and rest 110 patients were given corticosteroid 
injection. All the patients were selected based on the inclusion and exclusion 
criteria described. Patient were selected by random methods on lot basis.  
All patients were treated as Out Patient. All the patients underwent same 
method of treatment. All the patients were assessed based on the numerical 
pain scoring system which will be described. Among the study group 71% of  
Dominant  hand involvement is found. 
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INCLUSION CRITERIA 
1. Pain more than 3 months after failed conservative treatment 
2. Patients should have pain score more than eight at the time of PRP 
 and corticosteroid injection. 
3. Patients should not had a local steroid injection in last 2months 
4. Both male and female 
5. Age- 18 years and above   
6. Pain and tenderness over the lateral aspect of elbow 
 
                   One of the test must be positive : 1. COZEN’S TEST 
            2. MILL’S MANEUVER 
          1. COZEN’S TEST: Ask the patient to make a firm fist. While the 
patient maintains this position, try to passively flex the wrist.  Patient will feel 
pain at the lateral epicondylar region. 
          2. MILL’S MANEUVER: While the patient keeps his/her elbow firmly 
straight and wrist flexed, pronation of the forearm initiates pain at the lateral 
epicondylar region. 
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EXCLUSION CRITERIA 
 Less than 3 months duration  
 Pain score less than eight 
 Patients with diabetes mellitus 
 Infection at the injection site 
 Thrombocytopenia 
 Patient on anti-platelet medications 
 Pregnancy 
 Patients younger than 18years 
Side effects after Corticosteroid injection 
1. Local hypopigmentation noted in 20% of cases 
2. No Allergic reactions in any of the cases  
Side effect was reported in one case after PRP injection. 
 On evaluation it was diagnosed to be biopsy proven tuberculous 
synovitis of elbow. He was started on Anti tuberculosis treatment.  
Subsequently patient recovered well. 
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INFORMED CONSENT 
After explaining the disease condition and treatment with PRP and 
Corticosteroid injection in their native language, informed consent was 
acquired from all the patients. All the patients agreed for the procedure and to 
participate in the study. The consent form was signed by all the patients and 
their nearest relative. 
CLINICAL DIAGNOSIS 
Diagnosis of tennis elbow was done when the patient experienced pain 
along the lateral aspect of the elbow joint. On dorsiflexion of wrist, this pain 
would worsen. On examination, localized tenderness was elicited over the 
lateral epicondyle of the patient. 
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NUMERICAL PAIN SCORE 
Numerical pain score is used as a subjective evaluation of pain. In this, 
the patient is asked to rate the intensity of the pain perceived by them. Score 
zero (0) means there is no pain. Score 10 refers to the worst pain possible. 
As per the Numerical pain score, pain intensity was categorized as mild, 
moderate and severe. 
 
 
 
 
 
 
 Score 0 to 3 -- MILD 
  Score 4 to 6 -- MODERATE 
  Score 7 to 10 -- SEVERE 
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PREPARATION OF PRP 
Platelet Rich Plasma was prepared using double spin centrifugation 
method. 15ml of patients own venous blood was withdrawn from antecubital 
vein under aseptic conditions and was collected in pre sterilized centrifuge four 
vacutainers vials. These centrifuge vials were preloaded with anticoagulant 
Acid Citrate Dextrose. This vacutainer was subjected to a first spin in a 
centrifuge at a speed of 2500 rpm for 10 minutes.  After the first spin three 
layers appear. 
 
 
 
 
 
 
 
 The top layers consist of PLATELET POOR PLASMA  
(It contains approximately 2,70,000 platelet cells / cu.mm) 
 The middle layers consist of PLATELETS AND LEUCOCYTES  
(It contains approximately 3,90,000 platelet cells / cu.mm)   
 The deep layers consist of RED BLOOD CELLS (It contains 
approximately 1,25,000 platelet cells / cu.mm) 
RBC
BUFFY 
COAT 
PLATELET 
POOR 
PLASMA 
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The top and middle layers were transferred to a fresh vacutainer. The 
plasma was then subjected to a second spin at a speed of 3500 rpm for  
15 minutes. The plasma at the bottom which is rich in platelets was separated 
and used for infiltration. The resulting platelets concentrate contains 6-8 times 
the concentration of platelets compared to baseline whole blood. 
PLATELET RICH PLASMA 
 The top most layer of second spin consist of PLATELET POOR 
PLASMA (It contains approximately 43,000 platelet cells / cu.mm) 
 The bottom layer of second spin consist of PLATELET RICH 
PLASMA (It contains approximately 10,25,000 platelet cells / cu.mm) 
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THE CENTRIFUGE USED  
FOR PRP PREPARATION 
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TECHNIQUE OF INFILTRATION 
The most tender point was palpated under ultrasound guidance and the 
point is marked using a skin marker and the site was prepared for injection. 
Under aseptic condition, using a 21G and 1 1/2 inch needle, 1ml PRP is 
injected initially over the site with maximum tenderness and the needle is 
partially withdrawn and multiple punctures are made in the surrounding tissue 
(peppering technique).  The surrounding tissue was injected with the remaining 
1ml of platelet rich plasma. 
 
 
 
 
 
 
  
DURING INJECTION 
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ULTRASOUND IMAGE OF PRP INJECTION 
 
 
 
 
 
 
 
 
 
YELLOW ARROW indicates 21G needle 
RED ARROW indicates heterogenous hypoechoic area 
PURPLEARROW indicates osteophytes 
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PLATELET ACTIVATION 
 As per Kenneth S Lee et al, needling of surrounding tissue will promote 
the activation of the platelets by means of release of thrombin from the fresh 
bleeding. This technique is used for platelet activation.22 
 
FOLLOW UP 
 Patients were followed up for 6 months. Follow up was done at second 
day after injection to find out any adverse reactions. All cases were protected 
with brace initially and given oral antibiotics for 1 weeks with cold 
fomentation, and then restoration with normal daily activities were allowed 
from the third week with stretching and physiotherapy. NSAIDS are 
contraindicated 1 week before and after the procedure. Opioid analgesics can 
be given.  Follow-up was done at 1, 2, 4, 6 months. Patients were assessed 
subjectively using the numerical pain score. 
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RESULTS AND ANALYSIS 
 
Patients were analyzed for pain relief subjectively at 1, 2, 4 and  
6 months. The results are given below. 
PERCENTAGE REDUCTION OF PAIN 
Patients were analyzed for percentage reduction of pain. Percentage 
reduction of pain is obtained by calculating the percentage of the difference of 
pain score at every follow-up from initial pain score at the time of injection. 
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PERCENTAGE REDUCTION OF PAIN IN PRP PATIENTS 
 
 
 
 
GENDER EXCELLENT GOOD POOR 
MALE 73% 20% 7% 
FEMALE 82% 14% 4% 
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PERCENTAGE OF PAIN REDUCTION IN CORTICOSTEROID GROUP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENDER EXCELLENT GOOD POOR 
MALE 36% 59% 5% 
FEMALE 37% 55% 8% 
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First month recoded 
GROUP Frequency Percent Valid Percent
PRP Valid 
0% pain relief 4 3.5 3.5 
1-49% 81 72.6 72.6 
50-99% 17 15.9 15.9 
100% 8 8.0 8.0 
Total 110 100.0 100.0 
CORTICOSTEROIDS Valid 
0% pain relief 6 4.7 4.7 
1-49% 86 79.4 79.4 
50-99% 12 10.3 10.3 
100% 6 5.6 5.6 
Total 110 100.0 100.0 
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Second month recoded 
GROUP Frequency Percent Valid Percent 
PRP Valid 
0% pain relief 4 3.5 3.5 
1-49% 63 56.6 56.6 
50-99% 26 23.9 23.9 
100% 17 15.9 15.9 
Total 110 100.0 100.0 
CORTICOSTEROIDS Valid 
0% pain relief 5 3.7 3.7 
1-49% 78 72.0 72.0 
50-99% 15 13.1 13.1 
100% 12 11.2 11.2 
     Total 110 100.0 100.0 
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Fourth month recoded 
GROUP Frequency Percent Valid Percent 
PRP Valid 
0% pain relief 4 3.5 3.5 
1-49% 8 8.0 8.0 
50-99% 80 71.7 71.7 
100% 18 16.8 16.8 
Total 110 100.0 100.0 
CORTICOSTEROIDS Valid 
0% pain relief 5 3.7 3.7 
1-49% 40 36.4 36.4 
50-99% 51 47.7 47.7 
100% 14 12.1 12.1 
Total 110 100.0 100.0 
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Sixth month recoded 
GROUP Frequency Percent Valid Percent 
PRP Valid 
0% pain relief 4 3.5 3.5 
1-49% 5 4.4 4.4 
50-99% 84 76.1 76.1 
100% 17 15.9 15.9 
Total 110 100.0 100.0 
CORTICOSTEROIDS Valid 
0% pain relief 4 3.7 3.7 
1-49% 28 25.2 25.2 
50-99% 65 59.8 59.8 
100% 13 11.2 11.2 
Total 110 100.0 100.0 
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STATISTICAL ANALYSIS 
T-TEST: 
Group Statistics 
 
GROUP N Mean Std. Deviation 
Std. 
Error 
Mean 
AT INJECTON
PRP 110 8.7788 .41693 .03922
CORTICOSTEROIDS 110 8.8785 .32824 .03173
First month 
PRP 110 5.7965 2.37607 .22352
CORTICOSTEROIDS 110 6.3084 2.22935 .21552
Second month 
PRP 110 4.2035 2.26053 .21265
CORTICOSTEROIDS 110 4.9065 2.15675 .20850
Fourth month 
PRP 110 2.8673 1.80032 .16936
CORTICOSTEROIDS 110 4.0561 1.93201 .18677
Sixth month 
PRP 110 2.2212 1.75120 .16474
CORTICOSTEROIDS 110 3.8318 1.90573 .18423
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Independent Samples Test 
 t-test for Equality of Means 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
AT INJECTON 
Equal variances assumed .051 -.09974 .05078
Equal variances not assumed .049 -.09974 .05045
First month 
Equal variances assumed .101 -.51195 .31104
Equal variances not assumed .101 -.51195 .31050
Second month 
Equal variances assumed .019 -.70300 .29820
Equal variances not assumed .019 -.70300 .29781
Fourth month 
Equal variances assumed .000 -1.18882 .25164
Equal variances not assumed .000 -1.18882 .25213
Sixth month 
Equal variances assumed .000 -1.61054 .24658
Equal variances not assumed .000 -1.61054 .24715
 
                               Our study was significant as the P value is <0.05  
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DISCUSSION 
 Protease inhibitor, adhesive proteins, coagulation factors are the 
biologically active substances present in platelet for clotting. Platelets also 
release TGF –beta 1, VEGF, PDGF, CGF. These help in the process of tissue 
healing by cellular differentiation and proliferation, angiogenesis, tissue debris 
removal, chemotaxis, and ECM formation.47 By direct local injection of 
autologous platelet rich concentrate, degenerative conditions like tennis elbow 
are treated. 
 Multiple methods are being used for the preparation of autologous 
Platelet Rich Plasma. The containers used for this preparation differs to 
minimize the direct blood-handling. The volume of Platelet Rich Plasma is 
usually 10 percent of the whole blood used. Alsousou J et al used a GPS 
system for preparation of PRP. The PRP volume of about 5 ml was collected 
following 12 minutes of rotations at 3200 rpm.4 Augustus D et al used a 
double centrifugation method which separates blood first into plasma and 
RBC.3 
 The Plasma formed was separated again in to Platelet Rich Plasma and 
platelet poor plasma by second centrifugation. In this study, Augustus D et al 
method of double centrifugation was used.3 By repeated trial and error method 
we standardized the procedure of preparation of platelet rich plasma. 
 Platelet rich concentrate, autologous platelet gel are synonyms for 
platelet rich plasma.45 Platelet rich plasma is defined as autologous blood with 
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a concentration of platelets above the base line values. The platelet counts in 
our samples ranged from two to six lakhs per cc. Hall M.P. et al described 
platelet rich plasma contains a two to eight fold increase in platelet 
concentration and 1-25 fold increase in growth factor concentration. According 
to Marx R E et al in an article “what is prp and what is not prp?” described 
that at least 10 lakhs of platelet per ml in five ml of plasma, will be associated 
with enhancement of healing.29 Alsousou J et al in a review article described a 
concentration of five times the normal count as working definition of PRP.4 
 ELISA can be used for measurement of concentration of the growth 
factors. Augustus D et al found that growth factors such as PDGF, IGF-1 will 
be increased in single centrifugation than in double centrifugation.3 
Measurement of growth factors are not done because their assay was not cost 
effective. 
 Depending on WBC concentration, PRP classified as low WBC PRP 
and high WBC PRP. Augustus D et al found that WBC count is reduced in 
platelet poor plasma and increased in platelet rich plasma.3 There were no 
significant difference in WBC cell types in platelet poor plasma and platelet 
rich plasma.3 Some authors suggested avoiding exposure of WBC to tissues so 
that inflammatory reaction may reduce.  
 Bielecki T M et al support the WBC presence as it increased release of 
growth factors and also has antibacterial actions.8 
 After release from circulation, platelets in PRP get activated.      
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Kenneth S Lee et al described that needle prick at the time of injection will 
induce bleeding which will provide the clotting factor thrombin needed for 
activating platelets. Addition of substances like bovine thrombin, calcium 
chloride and type 1 collagen for activating platelets.22 
 Most of the authors used similar technique of infiltration for PRP 
treatment. Keith s Hetchman et al, Joost C Peerbooms et al, Ertugrul Aksahin 
et al, Ehab Mohamed SelemRagab et al, used similar technique. They palpated 
the point of maximum tenderness and injected by single skin portal and five to 
six penetrations in surrounding tissues. This technique was known as 
peppering technique.  
           In our study, we used same technique for injecting platelet rich plasma 
in Tennis elbow patients. This was a prospective trial by study design 
conducted on 220 patients which includes 110 patients injected with PRP and 
110 patients injected with corticosteroid injection. 
 Both groups of patients were selected based on the inclusion criteria and 
exclusion criteria described. Patients having chronic inflammatory conditions 
like rheumatoid arthritis are excluded from the study. Assessment of 
progression was done based on numerical pain scoring system. 
Christos Thanases et al compared PRP to whole blood in the treatment for 
tennis elbow.9 Keith S Hetchman et al on 31 tennis elbow patients which was 
not responded for conservative treatment by single PRP injection.23 
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TWO PARALLEL STUDIES (PRP VS CORTICOSTEROID) 
 Samuel A Taylor et al on 100 tennis elbow patients compared between 
PRP and steroid injection.46 
 V V Reddy et al on 150 tennis elbow patients compared between PRP 
and corticosteroid. Both VAS and DASH score shows improvement in pain 
relief noted in PRP group compared than CORTICOSTEROID group at 26th 
and 52 weeks follow up.52 
 On linking the results at 1,2,4,6 months of follow up, it was established 
that patients got relieved of their pain in one month. But, only at two months 
there was noticeable relief of symptoms. No patients had repeat injections. The 
above results were comparable with Ertugrul Aksahin et al and Christos 
Thanases et al study. 
 The difference between 1, 2, 4 and 6 months pain reduction were tested 
for significance by paired T – test using SPS system. It was found that there 
was no notable difference in pain reduction between 2 months and 4 months,  
2 months and 6 months, 4 months and 6 months scores.  
 But there was major difference in pain score in 1 and 2 months. By 
testing independent samples T-test using equal variances assumed found that  
2 months, 4 months and 6 months pain reduction was considerably equal in all 
groups. 
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LIMITATIONS OF OUR STUDY 
 
1. A subjective evaluation was done based on patient’s insight of pain 
(VAS score) and the evaluation was not based on objective point of 
view (in the form of hand grip strength). 
 
2. Control group was used and therefore available for evaluation in this 
study. 
 
3. The concentration of platelets in PRP was not checked and standardized. 
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SUMMARY 
 
 Lateral epicondylitis is considered to be a degenerative tendinopathy, 
with recurrent micro trauma as the major cause. Autologous platelet rich 
plasma injections and corticosteroid injections are gaining popularity in the 
treatment of tendinopathies such as tennis elbow. Platelet rich plasma contains 
growth factors which help in healing of tissues. We conducted a study by 
intralesional autologous platelet rich plasma injections and corticosteroid 
injections in patients with tennis elbow.  
 
 This was a prospective study conducted on total 220 patients, out of this 
110 patients had autologous platelet rich plasma injection and 110 patients had 
corticosteroid injection for tennis elbow. 
 
Patients were analyzed for percentage reduction of pain. Percentage 
reduction of pain is obtained by calculating the percentage of the difference of 
pain score at every follow up from initial pain score at the time of injection. 
Out of 220 patients, 110 patients given PRP and 110 patients 
CORTICOSTEROIDS.  
 
 Based on inclusion and exclusion criteria patients were designated. 
Patients were given a single intralesional autologous PRP and corticosteroid 
injections by peppering technique. Platelet rich plasma was prepared by a 
double centrifugation method initially at 2500 rotations per minute for 10 
minutes and later at 3500 rotations per minute for 15 minutes.  
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15ml of blood was withdrawn out of which 2ml of PRP was attained. Cell 
count was analyzed from this PRP. The initial and 1 & 2, 4, 6 month’s 
numerical pain score was recorded and analyzed. 
 
In PRP group, 61 patients were male and 49 patients were female. 
Among male patients, based on VAS and DASH score 73% had excellent 
prognosis, 20% had good prognosis and 7% had poor prognosis. Among 
female patients, 82% had excellent prognosis, 14% had good prognosis and  
4 % had poor prognosis. 
 
In CORTICOSTEROID group, 61 patients were male and 49 patients 
were female. Among male patients, based on VAS and DASH score 36% had 
excellent prognosis, 59% had good prognosis and 5% had poor prognosis. 
Among female patients, 37% had excellent prognosis, 55% had good prognosis 
and 8 % had poor prognosis. 
 
In PRP group, among 58% of patients with right dominant side 
involvement, 40 % of patients returned to their normal routine labourer work 
without any pain, rest 18 % people started office works. 
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 No correlation was found in the period of symptoms to pain relief which 
were assessed. On conclusion, it was found that intralesional autologous 
platelet rich plasma injection was safe and useful in the treatment of tennis 
elbow and provided better benefits on long term basis as compared to 
corticosteroid injection.  
 In our study, maximum benefit was observed at 2 months. One patient 
developed pain and swelling of right elbow after 2 months of PRP injection. On 
evaluation it was diagnosed to be biopsy proven tuberculous synovitis of 
elbow. He was started on Anti tuberculosis treatment. Subsequently patient 
recovered well.  
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CONCLUSION 
 
 
Autologous PRP and CORTICOSTEROID injection is a safe and useful    
modality of treatment in the treatment of lateral epicondylitis. 
 
The response of patients with PRP was significantly better than 
CORTICOSTEROID injection in the treatment of lateral epicondylitis. 
 
Maximum benefit after PRP injection was observed at 2 months and 
sustained for at least 6 months. 
 
Corticosteroids are effective on short term basis only. But PRP is 
effective on long term basis. 
 
Also, we encourage more randomized clinical trials on this topic 
emphasizing on the number and frequency of injections as well as 
standardization of concentration of platelets in PRP to overcome limitations. 
 
In our study, we found Autologous PRP is found to be superior than 
corticosteroid. 
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CONSENT FORM 
 
Study detail: “A  Comparative Study in Efficacy of Autologous Platelet richplasma and  
  Corticosteroid injection in Lateral Epicondylitis” 
 
Study Centre :Govt. Kilpauk Medical College & Hospital, Chennai. 
 
Patients Name     :  
 
Patients Age : 
 
Identification No :  
 
Patient may check ( ) these boxes 
 
I confirm that I have understood the purpose of procedure for the above study. I had the 
opportunity to ask question and all my questions and doubts have been answered to my complete 
satisfaction. 
 
I understand that my participation in the study is voluntary and that I am free to withdraw at any 
time without giving reason, without my legal rights being affected. 
 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the ethical 
committee and the regulatory authorities will not need my permission to look at my health records, 
both in respect of current study and any further research that may be conducted in relation to it, 
even if I withdraw from the study I agree to this access. However, I understand that my identity will 
not be revealed in any information released to third parties or published, unless as required under 
the law. I agree not to restrict the use of any data or results that arise from this study. 
 
I hereby make known that I have fully understood the use of above surgical procedure, the possible 
complications arising out of its use and the same was clearly explained to me and also understand 
that this technique is a new method of treatment of patella fractures and this study is done to know 
the usefulness of the same in management of patella fractures 
 
I agree to take part in the above study and to comply with the instructions given during the study and 
faithfully cooperate with the study team and to immediately inform the study staff if I suffer from any 
deterioration in my health or well-being or any unexpected or unusual symptoms. 
 
I hereby consent to participate in this study. 
 
I hereby give permission to undergo complete clinical examination and diagnostic tests including 
hematological, biochemical, radiological tests. 
 
Signature/thumb impression: 
 
 
Patients Name and Address:   Place :   Date : 
 
 
Signature of investigator 
 
  
A COMPARATIVE STUDY IN EFFICACY OF ULTRASOUND 
GUIDED AUTOLOGOUS PLATELET RICH PLASMA AND 
CORTICOSTEROID INJECTION IN LATERAL EPICONDYLITIS” 
Investigator : Dr.M.Rajadurai 
 
PATIENT DETAILS: 
 
Name    : 
Age       : 
Sex    : 
Hospital Number  : 
Disease   : 
Duration of Symptoms : 
Pain Score   : 
Date of Injection  : 
Follow Ups 
 
1st Month 2nd Month 4th Month 6th Month 
    
 
 
  
MASTER CHART 
 
 
SL 
NO NAME AGE SEX TYPE OF INJECTION
DURATION 
OF PAIN 
PAIN SCORE 
AT TIME OF 
INJECTION 
PAIN 
SCORE 
AT 1ST 
MONTH 
PAIN 
SCORE 
AT 2ND 
MONTH 
PAIN 
SCORE 
AT 4TH 
MONTH 
PAIN 
SCORE AT 
6TH MONTH 
1 VIJAYA 43 F PRP 7 MONTHS 9 0 0 0 0 
2 PALANI 40 M CORTICOSTEROID 6 MONTHS 8 4 3 3 3 
3 SUBASH 43 M CORTICOSTEROID 4 MONTHS 9 8 8 8 8 
4 SUSEELA 56 F PRP 5 MONTHS 9 0 0 0 0 
5 SELVI 37 F PRP 6 MONTHS 8 2 0 0 0 
6 SAKTHI 48 F PRP 3 MONTHS 9 4 3 3 3 
7 JANAKI 39 F CORTICOSTEROID 1 YEAR 9 6 4 4 4 
8 VALLI 55 F PRP 3 MONTHS 9 0 0 0 0 
9 BHARAT 38 M PRP 5 MONTHS 8 8 8 8 8 
10 RAMAN 38 M PRP 1 YEAR 9 6 0 0 0 
11 MARIYAN 48 M CORTICOSTEROID 8 MONTHS 8 8 8 8 8 
12 SUMAN 36 M CORTICOSTEROID 1 ½ YEAR 8 6 2 0 0 
13 GANESH 60 M PRP 6 MONTHS 9 0 0 0 0 
14 GOKUL 54 M PRP 3 MONTHS 8 6 4 4 6 
15 VIJI 55 M CORTICOSTEROID 1 YEAR 9 0 0 0 0 
16 SENBAGAM 36 F CORTICOSTEROID 1 YEAR 9 2 0 2 8 
17 SELVAM 49 M PRP 1 YEAR 8 8 8 8 8 
18 UMA 39 F PRP 3 MONTHS 9 2 0 0 0 
19 MAHESH 36 M PRP 1 YEAR 8 8 8 8 8 
20 PANDIYAN 38 M CORTICOSTEROID 1 ½ YEAR 8 2 0 0 0 
21 PADMINI 59 F CORTICOSTEROID 8 MONTHS 9 1 0 0 0 
22 RAJA 45 M PPR 3 MONTHS 8 0 0 0 0 
23 KALIYAN 55 M CORTICOSTEROID 3 MONTHS 9 0 0 0 0 
24 MANJU 28 F CORTICOSTEROID 6 MONTHS 9 2 0 0 0 
25 VENKAT  38 M PRP 
5 
MONTHS 8 0 0 0 0 
SL 
NO NAME AGE SEX TYPE OF INJECTION
DURATION 
OF PAIN 
PAIN SCORE 
AT TIME OF 
INJECTION 
PAIN 
SCORE 
AT 1ST 
MONTH 
PAIN 
SCORE 
AT 2ND 
MONTH 
PAIN 
SCORE 
AT 4TH 
MONTH 
PAIN 
SCORE AT 
6TH MONTH 
26 ANNIE 58 F CORTICOSTEROID 1 YEARS 9 7 5 5 6 
27 DHANAM 49 F PRP 3 MONTHS 8 6 4 4 4 
28 SENTHIL 31 M CORTICOSTEROID 3 MONTHS 9 0 8 6 6 
29 SAVITHA 49 F PRP 1 ½ YEARS 8 3 0 0 0 
30 RAVICHANDRAN 40 M PRP 1 YEAR 8 6 3 3 3 
31 THIRUPATHI 51 M CORTICOSTEROID 8 MONTHS 8 6 4 4 4 
32 GOVIND 50 M CORTICOSTEROID 6 MONTHS 9 9 0 0 0 
33 LALITHA 48 F PRP 5 MONTHS 9 8 6 5 5 
34 LAKSHMI 47 F PRP 4 MONTHS 9 3 2 2 2 
35 THANGAM 50 M PRP 6 MONTHS 9 0 0 0 0 
36 PARASURAMA N 49 M CORTICOSTEROID 3 MONTHS 9 0 0 0 0 
37 DARANI 27 M PRP 8 MONTHS 9 8 6 4 2 
38 MYTHILI 31 F CORTICOSTEROID 6 MONTHS 9 0 0 0 2 
39 SHANGAVI 46 F CORTICOSTEROID 3 MONTHS 9 6 6 6 6 
40 DEVAN 49 M CORTICOSTEROID 4 MONTHS 9 2 1 0 0 
41 NARAYAN 54 M PRP 6 MONTHS 9 0 0 0 0 
42 MOORTHY 69 M PRP 8 MONTHS 9 0 0 0 0 
43 PREM 49 M PRP 1 YEAR 9 9 9 9 9 
44 POOJA 48 F CORTICOSTEROID 1 ½ YEARS 9 9 9 9 9 
45 VENKATESAN 59 M PRP 1 ½ YEARS 9 2 0 0 0 
46 SARASU 30 F PRP 8 MONTHS 8 6 4 4 4 
47 RANIYAMMAL 48 F CORTICOSTEROID 3 MONTHS 9 9 9 9 9 
48 SIGARAM 39 M CORTICOSTEROID 6 MONTHS 9 0 0 0 0 
SL 
NO NAME AGE SEX TYPE OF INJECTION
DURATION 
OF PAIN 
PAIN SCORE 
AT TIME OF 
INJECTION 
PAIN 
SCORE 
AT 1ST 
MONTH 
PAIN 
SCORE 
AT 2ND 
MONTH 
PAIN 
SCORE 
AT 4TH 
MONTH 
PAIN 
SCORE AT 
6TH MONTH 
49 KAVI 34 M PRP 8 MONTHS 8 4 1 1 1 
50 RUKKU 43 F CORTICOSTEROID 1 ½ YEARS 9 9 9 9 9 
51 USHA 56 F PRP 6 MONTHS 9 7 3 2 2 
52 PADMA 54 F PRP 1 ½ YEARS 9 7 7 7 7 
53 SAVARIMUTHU 49 M PRP 8 MONTHS 9 5 2 0 0 
54 MARIAPPAN 63 M PRP 5 MONTHS 8 3 0 0 0 
55 MUTHU 54 M CORTICOSTEROID 6 MONTHS 8 4 4 4 4 
56 ANITHA 40 F PRP 3 MONTHS 9 4 0 0 0 
57 JAYAM 64 F PRP 8 MONTHS 8 3 3 3 3 
58 BHUVANESH 32 M PRP 9 MONTHS 8 4 0 0 5 
59 SAROJA 69 F PRP 6 MONTHS 9 3 3 3 3 
60 PARVEEN 40 M CORTICOSTEROID 9 MONTHS 8 2 0 0 0 
61 GOKUL 40 M PRP 3 MONTHS 8 3 2 2 2 
62 SUNDAR 30 M CORTICOSTEROID 6 MONTHS 8 4 4 4 4 
63 KALA 30 F CORTICOSTEROID 5 MONTHS 9 7 3 3 3 
64 MANOJ 40 M PRP 8 MONTHS 8 2 2 2 2 
65 PALANI 50 M PRP 1 ½ YEARS 9 2 0 0 0 
66 VIJAYA 50 F CORTICOSTEROID 1 YEAR 8 4 0 0 0 
67 KUTTI 60 F PRP 2 YEARS 8 3 3 3 3 
68 VIJAY 57 M PRP 8 MONTHS 9 4 3 3 3 
69 VARUN 40 M PRP 9 MONTHS 9 7 3 2 2 
70 SEELA 59 F CORTICOSTEROID 3 MONTHS 9 3 3 3 3 
71 RANI 45 F PRP 7 MONTHS 9 5 5 3 3 
SL 
NO NAME AGE SEX TYPE OF INJECTION
DURATION 
OF PAIN 
PAIN SCORE 
AT TIME OF 
INJECTION 
PAIN 
SCORE 
AT 1ST 
MONTH 
PAIN 
SCORE 
AT 2ND 
MONTH 
PAIN 
SCORE 
AT 4TH 
MONTH 
PAIN 
SCORE AT 
6TH MONTH 
72. KANNAN 50 M PRP 9 MONTHS 9 6 4 4 4 
73 KARUPPAN 43 M CORTICOSTEROID 9 MONTHS 9 5 3 3 3 
74 ANITHA 32 F CORTICOSTEROID 8 MONTHS 9 6 5 4 4 
75 SUBA 34 F CORTICOSTEROID 9 MONTHS 9 8 5 5 4 
76 RAJA 42 M PRP 6 MONTHS 8 6 4 2 2 
77 KUMAR 33 M CORTICOSTEROID 8 MONTHS 9 8 5 4 4 
78 PRABHU 45 M PRP 1 YEAR 9 6 3 2 2 
79 SAKTHI 35 F PRP 9 MONTHS 9 5 4 4 4 
80 KUPPUSAMY 38 M CORTICOSTEROID 8 MONTHS 9 7 5 4 4 
81 RAJAN 56 M CORTICOSTEROID 7 MONTHS 8 6 6 5 5 
82 VIJAY 47 M CORTICOSTEROID 8 MONTHS 9 6 5 4 4 
83 DURAI 45 M CORTICOSTEROID 10 MONTHS 9 6 4 4 3 
84 KAVITHA 46 F PRP 9 MONTHS 9 4 4 3 3 
85 KAVIYA 55 F PRP 9 MONTHS 9 6 3 3 2 
86 KANNIYAMMAL 43 F CORTICOSTEROID 8 MONTHS 9 7 6 6 6 
87 ARPUTHAM 60 F CORTICOSTEROID 6 MONTHS 8 6 6 5 4 
88 TAMIL 43 F PRP 7 MONTHS 9 6 4 3 3 
89 KANMANI 45 F PRP 9 MONTHS 9 7 7 5 5 
90 ARUN 54 M CORTICOSTEROID 7 MONTHS 9 8 7 7 6 
91 KARTHIK 45 M CORTICOSTEROID 1.5 YEARS 9 6 5 4 4 
92 VIMALA 35 F CORTICOSTEROID 1 YEAR 9 7 6 6 5 
93 THARUN 45 M PRP 9 MONTHS 9 5 5 3 3 
94 SHANTHI 46F F PRP 10 MONTHS 9 6 5 5 3 
SL 
NO NAME AGE SEX TYPE OF INJECTION
DURATION 
OF PAIN 
PAIN SCORE 
AT TIME OF 
INJECTION 
PAIN 
SCORE 
AT 1ST 
MONTH 
PAIN 
SCORE 
AT 2ND 
MONTH 
PAIN 
SCORE 
AT 4TH 
MONTH 
PAIN 
SCORE AT 
6TH MONTH 
95 BALU 42 M CORTICOSTEROID 11 MONTHS 9 6 4 4 4 
96 KARPAGAM 35 F CORTICOSTEROID 7 MONTHS 9 5 5 4 3 
97 AROKIYAM 48 F CORTICOSTEROID 9 MONTHS 9 6 6 5 3 
98 KANNAN 40 M PRP 8 MONTHS 9 6 5 2 2 
99 RAJ 43 M PRP 6 MONTHS 9 5 5 3 2 
100 VINOTH 35 M CORTICOSTEROID 7 MONTHS 8 6 5 5 4 
101 PANDI 45 M CORTICOSTEROID 9 MONTHS 9 7 7 4 4 
102 RAVI 35 M CORTICOSTEROID 11 MONTHS 9 8 6 5 3 
103 MUTHU 54 M PRP 8 MONTHS 9 7 5 3 3 
104 DEVI 43 F CORTICOSTEROID 9 MONTHS 9 8 7 6 4 
105 MEENA 40 F PRP 5 MONTHS 9 7 5 3 2 
106 RADHIKA 35 F CORTICOSTEROID 9 MONTHS 9 7 6 5 5 
107 ARUMUGAM 34 M CORTICOSTEROID 1 YEAR 9 8 7 5 4 
108 KANDHAN 51 M PRP 8 MONTHS 9 7 5 4 3 
109 PRIYA 35 F PRP 9 MONTHS 9 8 5 3 2 
110 PRAVEENA 38 F CORTICOSTEROID 10 MONTHS 9 7 7 4 3 
111 SAMYKANNU 40 M CORTICOSTEROID 1.5 YEARS 9 8 5 5 5 
112 SONIYA 38 F PRP 10 MONTHS 9 8 6 5 4 
113 MURUGAN 50 M PRP 6 MONTHS 9 8 4 3 2 
114 MURALI 54 M CORTICOSTEROID 8 MONTHS 9 8 5 5 5 
115 MUTHUSAMY 47 M CORTICOSTEROID 7 MONTHS 9 8 6 4 3 
116 RAVICHANDRAN 45 M CORTICOSTEROID 9 MONTHS 9 7 7 5 5 
117 ARUNMOZHI 47 F PRP 7 MONTHS 9 7 6 3 3 
SL 
NO NAME AGE SEX TYPE OF INJECTION
DURATION 
OF PAIN 
PAIN SCORE 
AT TIME OF 
INJECTION 
PAIN 
SCORE 
AT 1ST 
MONTH 
PAIN 
SCORE 
AT 2ND 
MONTH 
PAIN 
SCORE 
AT 4TH 
MONTH 
PAIN 
SCORE AT 
6TH MONTH 
118 DEVA 35 M PRP 6 MONTHS 9 8 6 5 3 
119 RANI1 38 F CORTICOSTEROID 8 MONTHS 9 8 6 5 5 
120 KAMATCHI 40 F CORTICOSTEROID 9 MONTHS 9 8 7 6 5 
121 THENMOZHI 35 F PRP 8 MONTHS 9 7 7 5 3 
122 SHANKAR 46 M PRP 10 MONTHS 9 7 6 3 2 
123 BABU 43 M PRP 6 MONTHS 9 8 6 3 1 
124 TAMILSELVAN 50 M CORTICOSTEROID 8 MONTHS 9 7 5 3 2 
125 PRAVEEN 35 M CORTICOSTEROIDS 7 MONTHS 9 8 6 3 2 
126 LEELA 42 F PRP 5 MONTHS 8 7 5 2 2 
127 NARAYANAN 32 M PRP 6 MONTHS 9 7 7 3 2 
128 PREM 34 M CORTICOSTEROIDS 4 MONTHS 9 7 7 5 3 
129 KUMUTHA 56 F PRP 8 MONTHS 9 7 6 3 1 
130 JANA 35 M PRP 5 MONTHS 9 8 5 2 1 
131 SUDHARSAN 40 M CORTICOSTEROIDS 8 MONTHS 9 8 6 4 4 
132 VIGNESH 45 M CORTICOSTEROIDS 7 MONTHS 9 8 5 3 3 
133 DHIVYA 34 F PRP 4 MONTHS 8 7 5 3 2 
134 LAKSHMI 51 F PRP 5 MONTHS 9 7 6 3 2 
135 KAVITHA 43 F CORTICOSTEROIDS 6 MONTHS 9 8 4 3 3 
136 YUVRANI 30 F CORTICOSTEROIDS 8 MONTHS 9 7 6 4 3 
137 RAJAMMAL 48 F PRP 5 MONTHS 8 6 5 3 1 
138 GOUTHAM 45 M PRP 6 MONTHS 9 7 6 4 2 
139 MARIMUTHU 47 M CORTICOSTEROIDS 9 MONTHS 9 8 6 5 5 
140 ARAVINTH 56 M CORTICOSTEROID 8 MONTHS 9 7 6 4 3 
SL 
NO NAME AGE SEX TYPE OF INJECTION
DURATION 
OF PAIN 
PAIN SCORE 
AT TIME OF 
INJECTION 
PAIN 
SCORE 
AT 1ST 
MONTH 
PAIN 
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AT 2ND 
MONTH 
PAIN 
SCORE 
AT 4TH 
MONTH 
PAIN 
SCORE AT 
6TH MONTH 
141 PRABHU 46 M PRP 7 MONTHS 8 6 4 2 1 
142 SUNDAR 34 M CORTICOSTEROIDS 6 MONTHS 9 8 5 3 3 
143 USHA 50 F CORTICOSTEROIDS 5 MONTHS 9 8 6 4 3 
144 RAMKUMAR 56 M PRP 8 MONTHS 9 7 5 2 2 
145 NAGARAJ 35 M PRP 7 MONTHS 9 8 6 3 2 
146 DEVAN 52 M CORTICOSTEROIDS 8 MONTHS 9 7 6 5 5 
147 VENKATESH 40 M PRP 7 MONTHS 8 7 5 2 1 
148 ISAIVANI 46 F CORTICOSTEROIDS 6 MONTHS 9 8 6 4 4 
149 AMUTHA 32 F CORTICOSTEROIDS 5 MONTHS 9 7 5 4 3 
150 EASAN 56 M PRP 7 MONTHS 9 7 5 3 1 
151 KUMARI 28 F PRP 6 MONTHS 9 8 5 3 2 
152 ANTONY 45 M CORTICOSTEROIDS 9 MONTHS 9 7 6 5 5 
153 CHITRA 35 M CORTICOSTEROIDS 8 MONTHS 9 7 5 4 4 
154 JAMAL 43 M CORTICOSTEROIDS 6 MONTHS 9 8 6 4 4 
155 MALA 43 F PRP 9 MONTHS 9 6 5 4 2 
156 JEYANTHI 45 F CORTICOSTEROIDS 6 MONTHS 9 7 5 5 5 
157 PALANI 47 M PRP 7 MONTHS 9 8 6 3 3 
158 SASIREKHA 35 F CORTICOSTEROIDS 5 MONTHS 9 7 5 5 4 
159 NANDHAGOPAL 55 M PRP 1 YEAR 9 7 6 3 2 
160 RAMAR 40 M PRP 9 MONTHS 9 8 5 3 2 
161 SAMUNDESHWARI 36 F CORTICOSTEROIDS 9 MPNTHS 9 7 5 4 4 
162 SELVAM 33 M PRP 6 MONTHS 9 8 6 3 1 
163 AFROZ 47 M CORTICOSTEROIDS 7 MONTHS 9 8 5 4 4 
SL 
NO NAME AGE SEX TYPE OF INJECTION
DURATION 
OF PAIN 
PAIN SCORE 
AT TIME OF 
INJECTION 
PAIN 
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PAIN 
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AT 4TH 
MONTH 
PAIN 
SCORE AT 
6TH MONTH 
164 AMUL 46 F PRP 9 MONTHS 9 8 7 3 2 
165 AMUTHA 45 F CORTICOSTEROIDS 7 MONTHS 9 6 6 4 4 
166 BALAMURUGAN 36 M PRP 6 MONTHS 8 6 6 6 4 
167 BALU 29 M CORTICOSTEROIDS 8 MONTHS 9 6 5 5 5 
168 DEVI 36 F CORTICOSTEROIDS 4 MONTHS 9 7 4 4 4 
169 DHANALAKSHMI 44 F CORTICOSTEROIDS 8 MONTHS 9 8 6 5 4 
170 GANGA 37 F PRP 7 MONTHS 9 7 5 3 2 
171 GOVINDHAMMAL 41 F PRP 8 MONTHS 9 7 5 4 2 
172 IMMUNUVEL 45 M PRP 9 MONTHS 9 8 6 5 3 
173 JEEVA 43 M CORTICOSTEROIDS 8 MONTHS 9 7 6 5 5 
174 KALAIVANI 32 F PRP 6 MONTHS 9 8 6 4 2 
175 KALAVATHY 50 F CORTICOSTEROIDS 5 MONTHS 8 7 5 4 4 
176 KAMALA 40 F PRP 9 MONTHS 9 7 6 4 2 
177 KRISHNAVENI 35 F PRP 5 MONTHS 9 7 5 3 1 
178 MANJULA 38 F CORTICOSTEROIDS 10 MONTHS 9 7 6 4 4 
179 MARIKANNAN 44 M CORTICOSTEROIDS 7 MONTHS 9 8 6 5 5 
180 MEENA 38 F CORTICOSTEROIDS 8 MONTHS 9 7 6 4 4 
181 NAGAVALLI 39 F PRP 6 MONTHS 9 8 7 4 2 
182 PADMINI 29 F PRP 7 MONTHS 9 8 6 5 2 
183 PRAKASH 30 M PRP 5 MONTHS 9 7 5 4 2 
184 RAJ 38 M CORTICOSTEROIDS 4 MONTHS 9 6 5 4 4 
185 RAMALINGAM 43 M CORTICOSTEROIDS 7 MONTHS 9 8 6 5 3 
186 RANJANI 39 F PRP 8 MONTHS 9 7 6 3 2 
SL 
NO NAME AGE SEX TYPE OF INJECTION
DURATION 
OF PAIN 
PAIN SCORE 
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PAIN 
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PAIN 
SCORE 
AT 2ND 
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PAIN 
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AT 4TH 
MONTH 
PAIN 
SCORE AT 
6TH MONTH 
187 SAMUVEL 43 M CORTICOSTEROIDS 9 MONTHS 9 7 6 4 4 
188 SARASWATHY 34 F CORTICOSTEROIDS 4 MONTHS 9 7 6 5 4 
189 SARAVANAN 45 M PRP 7 MONTHS 9 8 6 3 2 
190 SATHYA 37 F PRP 9 MONTHS 9 7 6 3 2 
191 SEETHALAKSHMI 41 F CORTICOSTEROIDS 6 MONTHS 9 8 6 5 4 
192 SETHURAMALINGAM 43 M PRP 5 MONTHS 9 7 5 3 3 
193 SHANTHI 36 F PRP 8 MONTHS 9 8 
6 
 
 
4 3 
194 SHARMILA 38 F PRP 9 MONTHS 9 7 6 4 2 
195 SHOBANA 30 F CORTICOSTEROIDS 7 MONTHS 9 8 7 6 5 
196 SUMATHY 29 F CORTICOSTEROIDS 8 MONTHS 9 7 5 4 4 
197 SURESHKUMAR 50 M PRP 1 YEAR 9 7 5 3 2 
198 VENKATESAN 38 M CORTICOSTEROIDS 6 MONTHS 9 7 5 4 3 
199 VENUGOPAL 36 M CORTICOSTEROIDS 7 MONTHS 9 7 5 4 4 
200 VIMALA 45 F PRP 9 MONTHS 9 7 5 4  2 
201 GOPI 33 M CORTICOSTEROIDS 9 MONTHS 9 7 6 5 5 
202 EZHIL 49 M PRP 10 MONTHS 9 7 4 3 2 
203 DINESH 46 M CORTICOSTEROIDS 9 MONTHS 9 6 5 4 4 
204 GUNASEKAR 31 M PRP 9 MONTHS 9 7 5 2 2 
205 PAKKIYAM 48 F CORTICOSTEROIDS 1 YEAR 9 7 6 5 5 
206 SASIKALA 30 F PRP 9 MONTHS 9 7 5 3 2 
207 RAJU 43 M CORTICOSTEROIDS 9 MONTHS 9 7 6 4 4 
208 ARAVINTH 37 M PRP 10 MONTHS 9 7 5 3 2 
209 HARISH 41 M CORTICOSTEROIDS 9 MONTHS 9 7 5 4 4 
SL 
NO NAME AGE SEX TYPE OF INJECTION
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OF PAIN 
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INJECTION 
PAIN 
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PAIN 
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AT 4TH 
MONTH 
PAIN 
SCORE AT 
6TH MONTH 
21O YUVARAJ 33 M PRP 9 MONTHS 9 7 5 3 2 
211 VINOTHINI 45 F CORTICOSTEROIDS 10 MONTHS 9 6 5 3 3 
212 SIVA 39 M PRP 9 MONTHS 9 7 5 3 1 
213 KANNIYAPPAN 43 M CORTICOSTEROIDS 9 MONTHS 9 7 6 4 4 
214 JEGAN 28 M PRP 9 MONTHS 9 7 5 3 2 
215 MEGALA 41 F CORTICOSTEROIDS 10 MONTHS 9 8 5 5 5 
216 VINOTH 36 M CORTICOSTEROIDS 1 YEAR 9 7 5 3 1 
217 BALAN 38 M CORTICOSTEROIDS 9 MONTHS 9 7 5 4 4 
218 LATHA 42 F CORTICOSTEROIDS 9 MONTHS 9 6 5 3 2 
219 JAYABALAN 32 M CORTICOSTEROIDS 9 MONTHS 9 7 5 5 5 
220 JEYA 47 F CORTICOSTEROIDS 9 MONTHS 9 7 5 3 2 
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SL 
NO NAME AGE SEX 
TYPE OF 
INJECTION 
DURATI
ON OF 
PAIN 
PAIN SCORE 
AT TIME OF 
INJECTION 
PAIN 
SCORE 
AT 1ST 
MONTH 
PAIN 
SCORE 
AT 2ND 
MONTH 
PAIN 
SCORE 
AT 4TH 
MONTH 
PAIN 
SCORE AT 
6TH 
MONTH 
1 VIJAYA 43 F PRP 7 MONTHS 9 0 0 0 0 
2 PALANI 40 M CORTICOSTEROID 6 MONTHS 8 4 3 3 3 
3 SUBASH 43 M CORTICOSTEROID 4 MONTHS 9 8 8 8 8 
4 SUSEELA 56 F PRP 5 MONTHS 9 0 0 0 0 
5 SELVI 37 F PRP 6 MONTHS 8 2 0 0 0 
6 SAKTHI 48 F PRP 3 MONTHS 9 4 3 3 3 
7 JANAKI 39 F CORTICOSTEROID 1 YEAR 9 6 4 4 4 
8 VALLI 55 F PRP 3 MONTHS 9 0 0 0 0 
9 BHARAT 38 M PRP 5 MONTHS 8 8 8 8 8 
10 RAMAN 38 M PRP 1 YEAR 9 6 0 0 0 
11 MARIYAN 48 M CORTICOSTEROID 8 MONTHS 8 8 8 8 8 
12 SUMAN 36 M CORTICOSTEROID 1 ½ YEAR 8 6 2 0 0 
13 GANESH 60 M PRP 6 MONTHS 9 0 0 0 0 
14 GOKUL 54 M PRP 3 MONTHS 8 6 4 4 6 
15 VIJI 55 M CORTICOSTEROID 1 YEAR 9 0 0 0 0 
16 SENBAGAM 36 F CORTICOSTEROID 1 YEAR 9 2 0 2 8 
17 SELVAM 49 M PRP 1 YEAR 8 8 8 8 8 
18 UMA 39 F PRP 3 MONTHS 9 2 0 0 0 
19 MAHESH 36 M PRP 1 YEAR 8 8 8 8 8 
20 PANDIYAN 38 M CORTICOSTEROID 1 ½ YEAR 8 2 0 0 0 
21 PADMINI 59 F CORTICOSTEROID 8 MONTHS 9 1 0 0 0 
22 RAJA 45 M PPR 3 MONTHS 8 0 0 0 0 
23 KALIYAN 55 M CORTICOSTEROID 3 MONTHS 9 0 0 0 0 
24 MANJU 28 F CORTICOSTEROID 6 MONTHS 9 2 0 0 0 
SL 
NO NAME AGE SEX 
TYPE OF 
INJECTION 
DURATI
ON OF 
PAIN 
PAIN SCORE 
AT TIME OF 
INJECTION 
PAIN 
SCORE 
AT 1ST 
MONTH 
PAIN 
SCORE 
AT 2ND 
MONTH 
PAIN 
SCORE 
AT 4TH 
MONTH 
PAIN 
SCORE AT 
6TH 
MONTH 
25 VENKAT  38 M PRP 
5 
MONTHS 8 0 0 0 0 
26 ANNIE 58 F CORTICOSTEROID 1 YEARS 9 7 5 5 6 
27 DHANAM 49 F PRP 3 MONTHS 8 6 4 4 4 
28 SENTHIL 31 M CORTICOSTEROID 3 MONTHS 9 0 8 6 6 
29 SAVITHA 49 F PRP 1 ½ YEARS 8 3 0 0 0 
30 RAVICHANDRAN 40 M PRP 1 YEAR 8 6 3 3 3 
31 THIRUPATHI 51 M CORTICOSTEROID 8 MONTHS 8 6 4 4 4 
32 GOVIND 50 M CORTICOSTEROID 6 MONTHS 9 9 0 0 0 
33 LALITHA 48 F PRP 5 MONTHS 9 8 6 5 5 
34 LAKSHMI 47 F PRP 4 MONTHS 9 3 2 2 2 
35 THANGAM 50 M PRP 6 MONTHS 9 0 0 0 0 
36 PARASURAMA N 49 M CORTICOSTEROID 
3 
MONTHS 9 0 0 0 0 
37 DARANI 27 M PRP 8 MONTHS 9 8 6 4 2 
38 MYTHILI 31 F CORTICOSTEROID 6 MONTHS 9 0 0 0 2 
39 SHANGAVI 46 F CORTICOSTEROID 3 MONTHS 9 6 6 6 6 
40 DEVAN 49 M CORTICOSTEROID 4 MONTHS 9 2 1 0 0 
41 NARAYAN 54 M PRP 6 MONTHS 9 0 0 0 0 
42 MOORTHY 69 M PRP 8 MONTHS 9 0 0 0 0 
43 PREM 49 M PRP 1 YEAR 9 9 9 9 9 
44 POOJA 48 F CORTICOSTEROID 1 ½ YEARS 9 9 9 9 9 
45 VENKATESAN 59 M PRP 
1 ½ 
YEARS 9 2 0 0 0 
46 SARASU 30 F PRP 8 MONTHS 8 6 4 4 4 
SL 
NO NAME AGE SEX 
TYPE OF 
INJECTION 
DURATI
ON OF 
PAIN 
PAIN SCORE 
AT TIME OF 
INJECTION 
PAIN 
SCORE 
AT 1ST 
MONTH 
PAIN 
SCORE 
AT 2ND 
MONTH 
PAIN 
SCORE 
AT 4TH 
MONTH 
PAIN 
SCORE AT 
6TH 
MONTH 
47 RANIYAMMAL 48 F CORTICOSTEROID 
3 
MONTHS 9 9 9 9 9 
48 SIGARAM 39 M CORTICOSTEROID 6 MONTHS 9 0 0 0 0 
49 KAVI 34 M PRP 8 MONTHS 8 4 1 1 1 
50 RUKKU 43 F CORTICOSTEROID 1 ½ YEARS 9 9 9 9 9 
51 USHA 56 F PRP 6 MONTHS 9 7 3 2 2 
52 PADMA 54 F PRP 1 ½ YEARS 9 7 7 7 7 
53 SAVARIMUTHU 49 M PRP 
8 
MONTHS 9 5 2 0 0 
54 MARIAPPAN 63 M PRP 5 MONTHS 8 3 0 0 0 
55 MUTHU 54 M CORTICOSTEROID 6 MONTHS 8 4 4 4 4 
56 ANITHA 40 F PRP 3 MONTHS 9 4 0 0 0 
57 JAYAM 64 F PRP 8 MONTHS 8 3 3 3 3 
58 BHUVANESH 32 M PRP 9 MONTHS 8 4 0 0 5 
59 SAROJA 69 F PRP 6 MONTHS 9 3 3 3 3 
60 PARVEEN 40 M CORTICOSTEROID 9 MONTHS 8 2 0 0 0 
61 GOKUL 40 M PRP 3 MONTHS 8 3 2 2 2 
62 SUNDAR 30 M CORTICOSTEROID 6 MONTHS 8 4 4 4 4 
63 KALA 30 F CORTICOSTEROID 5 MONTHS 9 7 3 3 3 
64 MANOJ 40 M PRP 8 MONTHS 8 2 2 2 2 
65 PALANI 50 M PRP 1 ½ YEARS 9 2 0 0 0 
66 VIJAYA 50 F CORTICOSTEROID 1 YEAR 8 4 0 0 0 
67 KUTTI 60 F PRP 2 YEARS 8 3 3 3 3 
68 VIJAY 57 M PRP 8 MONTHS 9 4 3 3 3 
SL 
NO NAME AGE SEX 
TYPE OF 
INJECTION 
DURATI
ON OF 
PAIN 
PAIN SCORE 
AT TIME OF 
INJECTION 
PAIN 
SCORE 
AT 1ST 
MONTH 
PAIN 
SCORE 
AT 2ND 
MONTH 
PAIN 
SCORE 
AT 4TH 
MONTH 
PAIN 
SCORE AT 
6TH 
MONTH 
69 VARUN 40 M PRP 9 MONTHS 9 7 3 2 2 
70 SEELA 59 F CORTICOSTEROID 3 MONTHS 9 3 3 3 3 
71 RANI 45 F PRP 7 MONTHS 9 5 5 3 3 
72. KANNAN 50 M PRP 9 MONTHS 9 6 4 4 4 
73 KARUPPAN 43 M CORTICOSTEROID 9 MONTHS 9 5 3 3 3 
74 ANITHA 32 F CORTICOSTEROID 8 MONTHS 9 6 5 4 4 
75 SUBA 34 F CORTICOSTEROID 9 MONTHS 9 8 5 5 4 
76 RAJA 42 M PRP 6 MONTHS 8 6 4 2 2 
77 KUMAR 33 M CORTICOSTEROID 8 MONTHS 9 8 5 4 4 
78 PRABHU 45 M PRP 1 YEAR 9 6 3 2 2 
79 SAKTHI 35 F PRP 9 MONTHS 9 5 4 4 4 
80 KUPPUSAMY 38 M CORTICOSTEROID 8 MONTHS 9 7 5 4 4 
81 RAJAN 56 M CORTICOSTEROID 7 MONTHS 8 6 6 5 5 
82 VIJAY 47 M CORTICOSTEROID 8 MONTHS 9 6 5 4 4 
83 DURAI 45 M CORTICOSTEROID 10 MONTHS 9 6 4 4 3 
84 KAVITHA 46 F PRP 9 MONTHS 9 4 4 3 3 
85 KAVIYA 55 F PRP 9 MONTHS 9 6 3 3 2 
86 KANNIYAMMAL 43 F CORTICOSTEROID 8 MONTHS 9 7 6 6 6 
87 ARPUTHAM 60 F CORTICOSTEROID 6 MONTHS 8 6 6 5 4 
88 TAMIL 43 F PRP 7 MONTHS 9 6 4 3 3 
89 KANMANI 45 F PRP 9 MONTHS 9 7 7 5 5 
90 ARUN 54 M CORTICOSTEROID 7 MONTHS 9 8 7 7 6 
SL 
NO NAME AGE SEX 
TYPE OF 
INJECTION 
DURATI
ON OF 
PAIN 
PAIN SCORE 
AT TIME OF 
INJECTION 
PAIN 
SCORE 
AT 1ST 
MONTH 
PAIN 
SCORE 
AT 2ND 
MONTH 
PAIN 
SCORE 
AT 4TH 
MONTH 
PAIN 
SCORE AT 
6TH 
MONTH 
91 KARTHIK 45 M CORTICOSTEROID 1.5 YEARS 9 6 5 4 4 
92 VIMALA 35 F CORTICOSTEROID 1 YEAR 9 7 6 6 5 
93 THARUN 45 M PRP 9 MONTHS 9 5 5 3 3 
94 SHANTHI 46F F PRP 10 MONTHS 9 6 5 5 3 
95 BALU 42 M CORTICOSTEROID 11 MONTHS 9 6 4 4 4 
96 KARPAGAM 35 F CORTICOSTEROID 7 MONTHS 9 5 5 4 3 
97 AROKIYAM 48 F CORTICOSTEROID 9 MONTHS 9 6 6 5 3 
98 KANNAN 40 M PRP 8 MONTHS 9 6 5 2 2 
99 RAJ 43 M PRP 6 MONTHS 9 5 5 3 2 
100 VINOTH 35 M CORTICOSTEROID 7 MONTHS 8 6 5 5 4 
101 PANDI 45 M CORTICOSTEROID 9 MONTHS 9 7 7 4 4 
102 RAVI 35 M CORTICOSTEROID 11 MONTHS 9 8 6 5 3 
103 MUTHU 54 M PRP 8 MONTHS 9 7 5 3 3 
104 DEVI 43 F CORTICOSTEROID 9 MONTHS 9 8 7 6 4 
105 MEENA 40 F PRP 5 MONTHS 9 7 5 3 2 
106 RADHIKA 35 F CORTICOSTEROID 9 MONTHS 9 7 6 5 5 
107 ARUMUGAM 34 M CORTICOSTEROID 1 YEAR 9 8 7 5 4 
108 KANDHAN 51 M PRP 8 MONTHS 9 7 5 4 3 
109 PRIYA 35 F PRP 9 MONTHS 9 8 5 3 2 
110 PRAVEENA 38 F CORTICOSTEROID 10 MONTHS 9 7 7 4 3 
111 SAMYKANNU 40 M CORTICOSTEROID 1.5 YEARS 9 8 5 5 5 
112 SONIYA 38 F PRP 10 MONTHS 9 8 6 5 4 
SL 
NO NAME AGE SEX 
TYPE OF 
INJECTION 
DURATI
ON OF 
PAIN 
PAIN SCORE 
AT TIME OF 
INJECTION 
PAIN 
SCORE 
AT 1ST 
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113 MURUGAN 50 M PRP 6 MONTHS 9 8 4 3 2 
114 MURALI 54 M CORTICOSTEROID 8 MONTHS 9 8 5 5 5 
115 MUTHUSAMY 47 M CORTICOSTEROID 7 MONTHS 9 8 6 4 3 
116 RAVICHANDRAN 45 M CORTICOSTEROID 9 MONTHS 9 7 7 5 5 
117 ARUNMOZHI 47 F PRP 7 MONTHS 9 7 6 3 3 
118 DEVA 35 M PRP 6 MONTHS 9 8 6 5 3 
119 RANI1 38 F CORTICOSTEROID 8 MONTHS 9 8 6 5 5 
120 KAMATCHI 40 F CORTICOSTEROID 9 MONTHS 9 8 7 6 5 
121 THENMOZHI 35 F PRP 8 MONTHS 9 7 7 5 3 
122 SHANKAR 46 M PRP 10 MONTHS 9 7 6 3 2 
123 BABU 43 M PRP 6 MONTHS 9 8 6 3 1 
124 TAMILSELVAN 50 M CORTICOSTEROID 8 MONTHS 9 7 5 3 2 
125 PRAVEEN 35 M CORTICOSTEROIDS 7 MONTHS 9 8 6 3 2 
126 LEELA 42 F PRP 5 MONTHS 8 7 5 2 2 
127 NARAYANAN 32 M PRP 6 MONTHS 9 7 7 3 2 
128 PREM 34 M CORTICOSTEROIDS 4 MONTHS 9 7 7 5 3 
129 KUMUTHA 56 F PRP 8 MONTHS 9 7 6 3 1 
130 JANA 35 M PRP 5 MONTHS 9 8 5 2 1 
131 SUDHARSAN 40 M CORTICOSTEROIDS 8 MONTHS 9 8 6 4 4 
132 VIGNESH 45 M CORTICOSTEROIDS 7 MONTHS 9 8 5 3 3 
133 DHIVYA 34 F PRP 4 MONTHS 8 7 5 3 2 
134 LAKSHMI 51 F PRP 5 MONTHS 9 7 6 3 2 
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135 KAVITHA 43 F CORTICOSTEROIDS 6 MONTHS 9 8 4 3 3 
136 YUVRANI 30 F CORTICOSTEROIDS 8 MONTHS 9 7 6 4 3 
137 RAJAMMAL 48 F PRP 5 MONTHS 8 6 5 3 1 
138 GOUTHAM 45 M PRP 6 MONTHS 9 7 6 4 2 
139 MARIMUTHU 47 M CORTICOSTEROIDS 9 MONTHS 9 8 6 5 5 
140 ARAVINTH 56 M CORTICOSTEROID 8 MONTHS 9 7 6 4 3 
141 PRABHU 46 M PRP 7 MONTHS 8 6 4 2 1 
142 SUNDAR 34 M CORTICOSTEROIDS 6 MONTHS 9 8 5 3 3 
143 USHA 50 F CORTICOSTEROIDS 5 MONTHS 9 8 6 4 3 
144 RAMKUMAR 56 M PRP 8 MONTHS 9 7 5 2 2 
145 NAGARAJ 35 M PRP 7 MONTHS 9 8 6 3 2 
146 DEVAN 52 M CORTICOSTEROIDS 8 MONTHS 9 7 6 5 5 
147 VENKATESH 40 M PRP 7 MONTHS 8 7 5 2 1 
148 ISAIVANI 46 F CORTICOSTEROIDS 6 MONTHS 9 8 6 4 4 
149 AMUTHA 32 F CORTICOSTEROIDS 5 MONTHS 9 7 5 4 3 
150 EASAN 56 M PRP 7 MONTHS 9 7 5 3 1 
151 KUMARI 28 F PRP 6 MONTHS 9 8 5 3 2 
152 ANTONY 45 M CORTICOSTEROIDS 9 MONTHS 9 7 6 5 5 
153 CHITRA 35 M CORTICOSTEROIDS 8 MONTHS 9 7 5 4 4 
154 JAMAL 43 M CORTICOSTEROIDS 6 MONTHS 9 8 6 4 4 
155 MALA 43 F PRP 9 MONTHS 9 6 5 4 2 
156 JEYANTHI 45 F CORTICOSTEROIDS 6 MONTHS 9 7 5 5 5 
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157 PALANI 47 M PRP 7 MONTHS 9 8 6 3 3 
158 SASIREKHA 35 F CORTICOSTEROIDS 5 MONTHS 9 7 5 5 4 
159 NANDHAGOPAL 55 M PRP 1 YEAR 9 7 6 3 2 
160 RAMAR 40 M PRP 9 MONTHS 9 8 5 3 2 
161 SAMUNDESHWARI 36 F CORTICOSTEROIDS 9 MPNTHS 9 7 5 4 4 
162 SELVAM 33 M PRP 6 MONTHS 9 8 6 3 1 
163 AFROZ 47 M CORTICOSTEROIDS 7 MONTHS 9 8 5 4 4 
164 AMUL 46 F PRP 9 MONTHS 9 8 7 3 2 
165 AMUTHA 45 F CORTICOSTEROIDS 7 MONTHS 9 6 6 4 4 
166 BALAMURUGAN 36 M PRP 6 MONTHS 8 6 6 6 4 
167 BALU 29 M CORTICOSTEROIDS 8 MONTHS 9 6 5 5 5 
168 DEVI 36 F CORTICOSTEROIDS 4 MONTHS 9 7 4 4 4 
169 DHANALAKSHMI 44 F CORTICOSTEROIDS 8 MONTHS 9 8 6 5 4 
170 GANGA 37 F PRP 7 MONTHS 9 7 5 3 2 
171 GOVINDHAMMAL 41 F PRP 8 MONTHS 9 7 5 4 2 
172 IMMUNUVEL 45 M PRP 9 MONTHS 9 8 6 5 3 
173 JEEVA 43 M CORTICOSTEROIDS 8 MONTHS 9 7 6 5 5 
174 KALAIVANI 32 F PRP 6 MONTHS 9 8 6 4 2 
175 KALAVATHY 50 F CORTICOSTEROIDS 5 MONTHS 8 7 5 4 4 
176 KAMALA 40 F PRP 9 MONTHS 9 7 6 4 2 
177 KRISHNAVENI 35 F PRP 5 MONTHS 9 7 5 3 1 
178 MANJULA 38 F CORTICOSTEROIDS 10 MONTHS 9 7 6 4 4 
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179 MARIKANNAN 44 M CORTICOSTEROIDS 7 MONTHS 9 8 6 5 5 
180 MEENA 38 F CORTICOSTEROIDS 8 MONTHS 9 7 6 4 4 
181 NAGAVALLI 39 F PRP 6 MONTHS 9 8 7 4 2 
182 PADMINI 29 F PRP 7 MONTHS 9 8 6 5 2 
183 PRAKASH 30 M PRP 5 MONTHS 9 7 5 4 2 
184 RAJ 38 M CORTICOSTEROIDS 4 MONTHS 9 6 5 4 4 
185 RAMALINGAM 43 M CORTICOSTEROIDS 7 MONTHS 9 8 6 5 3 
186 RANJANI 39 F PRP 8 MONTHS 9 7 6 3 2 
187 SAMUVEL 43 M CORTICOSTEROIDS 9 MONTHS 9 7 6 4 4 
188 SARASWATHY 34 F CORTICOSTEROIDS 4 MONTHS 9 7 6 5 4 
189 SARAVANAN 45 M PRP 7 MONTHS 9 8 6 3 2 
190 SATHYA 37 F PRP 9 MONTHS 9 7 6 3 2 
191 SEETHALAKSHMI 41 F CORTICOSTEROIDS 6 MONTHS 9 8 6 5 4 
192 SETHURAMALINGAM 43 M PRP 5 MONTHS 9 7 5 3 3 
193 SHANTHI 36 F PRP 8 MONTHS 9 8 
6 
 
 
4 3 
194 SHARMILA 38 F PRP 9 MONTHS 9 7 6 4 2 
195 SHOBANA 30 F CORTICOSTEROIDS 7 MONTHS 9 8 7 6 5 
196 SUMATHY 29 F CORTICOSTEROIDS 8 MONTHS 9 7 5 4 4 
197 SURESHKUMAR 50 M PRP 1 YEAR 9 7 5 3 2 
198 VENKATESAN 38 M CORTICOSTEROIDS 6 MONTHS 9 7 5 4 3 
199 VENUGOPAL 36 M CORTICOSTEROIDS 7 MONTHS 9 7 5 4 4 
200 VIMALA 45 F PRP 9 MONTHS 9 7 5 4  2 
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201 GOPI 33 M CORTICOSTEROIDS 9 MONTHS 9 7 6 5 5 
202 EZHIL 49 M PRP 10 MONTHS 9 7 4 3 2 
203 DINESH 46 M CORTICOSTEROIDS 9 MONTHS 9 6 5 4 4 
204 GUNASEKAR 31 M PRP 9 MONTHS 9 7 5 2 2 
205 PAKKIYAM 48 F CORTICOSTEROIDS 1 YEAR 9 7 6 5 5 
206 SASIKALA 30 F PRP 9 MONTHS 9 7 5 3 2 
207 RAJU 43 M CORTICOSTEROIDS 9 MONTHS 9 7 6 4 4 
208 ARAVINTH 37 M PRP 10 MONTHS 9 7 5 3 2 
209 HARISH 41 M CORTICOSTEROIDS 9 MONTHS 9 7 5 4 4 
21O YUVARAJ 33 M PRP 9 MONTHS 9 7 5 3 2 
211 VINOTHINI 45 F CORTICOSTEROIDS 10 MONTHS 9 6 5 3 3 
212 SIVA 39 M PRP 9 MONTHS 9 7 5 3 1 
213 KANNIYAPPAN 43 M CORTICOSTEROIDS 9 MONTHS 9 7 6 4 4 
214 JEGAN 28 M PRP 9 MONTHS 9 7 5 3 2 
215 MEGALA 41 F CORTICOSTEROIDS 10 MONTHS 9 8 5 5 5 
216 VINOTH 36 M CORTICOSTEROIDS 1 YEAR 9 7 5 3 1 
217 BALAN 38 M CORTICOSTEROIDS 9 MONTHS 9 7 5 4 4 
218 LATHA 42 F CORTICOSTEROIDS 9 MONTHS 9 6 5 3 2 
219 JAYABALAN 32 M CORTICOSTEROIDS 9 MONTHS 9 7 5 5 5 
220 JEYA 47 F CORTICOSTEROIDS 9 MONTHS 9 7 5 3 2 
 
 
 
                                                                                               SL NO 166 PATIENT WAS DIAGNOSED AS TUBERCULOUS SYNOVITIS.  
